PATH: Form 990, tax year 2019
View the entire original 990 at ProPublica ↗
- Organization
- PATH (EIN 91-1157127)
- Tax period
- 2019-01-01 to 2019-12-31
- Filed
- 2020-11-12
- IRS object ID
- 202033179349305453
- Schema version
- 2019v5.1
- Source
- Download XML · Original 990 at ProPublica
Every field in the e-filed return. Faint text is the IRS element name, for citing.
- Return header
- Form 990
- Schedule A
- Schedule B
- Schedule C
- Schedule D
- Schedule F
- Schedule I
- Schedule J
- Schedule M
- Schedule O
- Schedule R
Return header ReturnHeader
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return | 2020-11-12T13:18:25-06:00 | ReturnTs |
| Tax Period End | 2019-12-31 | TaxPeriodEndDt |
Preparer Firm PreparerFirmGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Firm EIN | 521392008 | PreparerFirmEIN |
Preparer Firm Name PreparerFirmName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | GELMAN ROSENBERG & FREEDMAN | BusinessNameLine1Txt |
Preparer US Address PreparerUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 4550 MONTGOMERY AVE SUITE 800N | AddressLine1Txt |
| City | BETHESDA | CityNm |
| State Abbreviation | MD | StateAbbreviationCd |
| ZIP | 208142930 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return Type | 990 | ReturnTypeCd |
| Tax Period Begin | 2019-01-01 | TaxPeriodBeginDt |
Filer Filer
| Field | Value | IRS element (for citing) |
|---|---|---|
| EIN | 911157127 | EIN |
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | PATH | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Control | PATH | BusinessNameControlTxt |
| Phone | 2062853500 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 2201 WESTLAKE AVENUE NO 200 | AddressLine1Txt |
| City | SEATTLE | CityNm |
| State Abbreviation | WA | StateAbbreviationCd |
| ZIP | 98121 | ZIPCd |
Business Officer BusinessOfficerGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | BRIAN NEVILLE | PersonNm |
| Person Title | VP ACCOUNTING/FINANCIAL OPERATIONS | PersonTitleTxt |
| Phone | 2062853500 | PhoneNum |
| Signature | 2020-11-12 | SignatureDt |
| Discuss With Paid Preparer | Yes (1) | DiscussWithPaidPreparerInd |
Preparer Person PreparerPersonGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Person | RICHARD J LOCASTRO CPA | PreparerPersonNm |
| PTIN | P00288314 | PTIN |
| Phone | 3019519090 | PhoneNum |
Filing Security Information FilingSecurityInformation
IP Address IPAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| I Pv4 Address | 75.103.231.202 | IPv4AddressTxt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| IP | 2020-11-12 | IPDt |
| IP Tm | 14:18:16 | IPTm |
| IP Timezone | ES | IPTimezoneCd |
| Filing License Type | P | FilingLicenseTypeCd |
| At Submission Creation Device Id | FF16D77653F3D7C4C20B8532A1D3BA36122446EB | AtSubmissionCreationDeviceId |
| At Submission Filing Device Id | 5AB07A053B3A330C0D5964923757432F9BB68C3B | AtSubmissionFilingDeviceId |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Tax | 2019 | TaxYr |
| Build TS | 2021-01-29 14:40:06Z | BuildTS |
Form 990 IRS990
| Field | Value | IRS element (for citing) |
|---|---|---|
| Principal Officer | BRIAN NEVILLE | PrincipalOfficerNm |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 2201 WESTLAKE AVENUE NO 200 | AddressLine1Txt |
| City | SEATTLE | CityNm |
| State Abbreviation | WA | StateAbbreviationCd |
| ZIP | 98121 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gross Receipts | $383,749,661 | GrossReceiptsAmt |
| Group Return For Affiliates | 0 | GroupReturnForAffiliatesInd |
| Organization501c3 | Yes (X) | Organization501c3Ind |
| Website Address | WWW.PATH.ORG | WebsiteAddressTxt |
| Type Of Organization Corp | Yes (X) | TypeOfOrganizationCorpInd |
| Formation | 1981 | FormationYr |
| Legal Domicile State | WA | LegalDomicileStateCd |
| Activity Or Mission | SEE PART III, LINE 1. | ActivityOrMissionDesc |
| Voting Members Governing Body | 15 | VotingMembersGoverningBodyCnt |
| Voting Members Independent | 15 | VotingMembersIndependentCnt |
| Total Employee | 737 | TotalEmployeeCnt |
| Total Volunteers | 0 | TotalVolunteersCnt |
| Total Gross UBI | $0 | TotalGrossUBIAmt |
| Net Unrelated Bus Txbl Incm | $0 | NetUnrelatedBusTxblIncmAmt |
| PY Contributions Grants | $305,315,221 | PYContributionsGrantsAmt |
| CY Contributions Grants | $286,808,545 | CYContributionsGrantsAmt |
| PY Program Service Revenue | $1,500 | PYProgramServiceRevenueAmt |
| CY Program Service Revenue | $2,038 | CYProgramServiceRevenueAmt |
| PY Investment Income | $3,037,130 | PYInvestmentIncomeAmt |
| CY Investment Income | $6,723,428 | CYInvestmentIncomeAmt |
| PY Other Revenue | $980,560 | PYOtherRevenueAmt |
| CY Other Revenue | $836,870 | CYOtherRevenueAmt |
| PY Total Revenue | $309,334,411 | PYTotalRevenueAmt |
| CY Total Revenue | $294,370,881 | CYTotalRevenueAmt |
| PY Grants And Similar Paid | $62,762,146 | PYGrantsAndSimilarPaidAmt |
| CY Grants And Similar Paid | $55,619,080 | CYGrantsAndSimilarPaidAmt |
| PY Benefits Paid To Members | $0 | PYBenefitsPaidToMembersAmt |
| CY Benefits Paid To Members | $0 | CYBenefitsPaidToMembersAmt |
| PY Salaries Comp Emp Bnft Paid | $139,545,675 | PYSalariesCompEmpBnftPaidAmt |
| CY Salaries Comp Emp Bnft Paid | $131,590,498 | CYSalariesCompEmpBnftPaidAmt |
| PY Total Prof Fndrsng Expns | $0 | PYTotalProfFndrsngExpnsAmt |
| CY Total Prof Fndrsng Expns | $0 | CYTotalProfFndrsngExpnsAmt |
| CY Total Fundraising Expense | $2,679,350 | CYTotalFundraisingExpenseAmt |
| PY Other Expenses | $110,458,648 | PYOtherExpensesAmt |
| CY Other Expenses | $105,099,261 | CYOtherExpensesAmt |
| PY Total Expenses | $312,766,469 | PYTotalExpensesAmt |
| CY Total Expenses | $292,308,839 | CYTotalExpensesAmt |
| PY Revenues Less Expenses | -$3,432,058 | PYRevenuesLessExpensesAmt |
| CY Revenues Less Expenses | $2,062,042 | CYRevenuesLessExpensesAmt |
| Total Assets BOY | $237,501,233 | TotalAssetsBOYAmt |
| Total Assets EOY | $243,064,155 | TotalAssetsEOYAmt |
| Total Liabilities BOY | $202,931,874 | TotalLiabilitiesBOYAmt |
| Total Liabilities EOY | $204,045,574 | TotalLiabilitiesEOYAmt |
| Net Assets Or Fund Balances BOY | $34,569,359 | NetAssetsOrFundBalancesBOYAmt |
| Net Assets Or Fund Balances EOY | $39,018,581 | NetAssetsOrFundBalancesEOYAmt |
| Info In Schedule O Part III | Yes (X) | InfoInScheduleOPartIIIInd |
| Mission | PATH'S MISSION IS TO ADVANCE HEALTH EQUITY THROUGH INNOVATION AND PARTNERSHIPS. (CONTINUED ON SCHEDULE O) | MissionDesc |
| Significant New Program Srvc | 0 | SignificantNewProgramSrvcInd |
| Significant Change | 0 | SignificantChangeInd |
| Expense | $122,045,425 | ExpenseAmt |
| Grant | $18,889,335 | GrantAmt |
| Revenue | $38 | RevenueAmt |
| Desc | GLOBAL HEALTH PROGRAMS: PATH'S GLOBAL HEALTH PROGRAMS DIVISION IS RESPONSIBLE FOR PATH'S SCIENTIFIC EXPERTISE IN MALARIA AND NEGLECTED TROPICAL DISEASES; HIV AND TUBERCULOSIS; MATERNAL, NEWBORN, AND CHILD HEALTH AND NUTRITION; SEXUAL AND REPRODUCTIVE HEALTH; AND NONCOMMUNICABLE DISEASES. THE DIVISION ALSO OVERSEES PATH'S WORK IN HEALTH SYSTEMS INNOVATION AND DELIVERY, AND MANAGES OUR COUNTRY OFFICES.(SEE SCHEDULE O)MALARIA AND NEGLECTED TROPICAL DISEASES:PATH PARTNERS WITH GOVERNMENTS, THE PRIVATE SECTOR, AND FUNDERS ACROSS THE GLOBE TO BRING THE WORLD CLOSER TO MALARIA ERADICATION. MORE THAN 200 PATH STAFF MEMBERS WORK ON MALARIA IN MORE THAN 30 COUNTRIES. OUR STRATEGY INCLUDES OPTIMIZING THE DELIVERY OF CURRENT TOOLS AND APPROACHES TO ENSURE THEY REACH THE PEOPLE WHO NEED THEM, DEVELOPING NEW STRATEGIES FOR ELIMINATION, DEVELOPING NEXT-GENERATION TOOLS TO OVERCOME EMERGING CHALLENGES, AND CREATING INNOVATIVE PARTNERSHIPS AND FUNDING MODELS TO ENSURE OUR PROGRAMS ARE SUSTAINABLE AND EFFECTIVE. PATH-PIONEERED APPROACHES HAVE CONTRIBUTED TO REMARKABLE PROGRESS IN MALARIA, WITH NEARLY 7 MILLION LIVES SAVED SINCE 2000.IN 2019, OUR MALARIA CONTROL AND ELIMINATION PARTNERSHIP IN AFRICA (MACEPA) PROGRAM, FUNDED BY THE BILL & MELINDA GATES FOUNDATION, CONTINUED TO SUPPORT THE GOVERNMENTS OF ETHIOPIA, SENEGAL, AND ZAMBIA TOWARD THEIR MALARIA ELIMINATION GOALS. MACEPA'S WORK INCLUDED SCALING UP PREVENTION AND TREATMENT; EVALUATING THE LATEST, MOST SENSITIVE DIAGNOSTIC TESTS; ESTABLISHING RAPID REPORTING SYSTEMS; AND CONTINUING TO SUPPORT POPULATION-WIDE, DRUG-BASED STRATEGIES SUCH AS MASS DRUG ADMINISTRATION. THROUGH OUR PROGRAM FOR THE ADVANCEMENT OF MALARIA OUTCOMES (PAMO), FUNDED BY THE US PRESIDENT'S MALARIA INITIATIVE, PATH CONTINUED TO ASSIST THE GOVERNMENT OF ZAMBIA IN ITS EFFORTS TO ELIMINATE LOCAL MALARIA INFECTION AND DISEASE. IN 2019, PAMO PROVIDED TECHNICAL SUPPORT AND MENTORSHIP TO MORE THAN 1,200 HEALTH CARE WORKERS ACROSS FOUR PROVINCES TO IMPROVE THE QUALITY OF CARE. PAMO ALSO SUPPORTED THE DISTRIBUTION OF 115,416 INSECTICIDE-TREATED BEDNETS, ORGANIZED SOCIAL BEHAVIOR CHANGE ACTIVITIES (INCLUDING ENGAGING SCHOOLS AND PRINTING EDUCATIONAL MATERIALS), AND PROVIDED TECHNICAL AND MATERIAL SUPPORT FOR DATA QUALITY AUDITS IN HEALTH FACILITIES.ALSO IN ZAMBIA, THE VISUALIZE NO MALARIA PROJECT CONTINUED TO EXPAND. THIS PROJECT, A GROUNDBREAKING PARTNERSHIP BETWEEN PATH AND A COALITION OF TECHNOLOGY COMPANIES, EQUIPS HEALTH WORKERS AND OFFICIALS WITH REAL-TIME DATA VISUALIZATION TO SEE AND UNDERSTAND WHERE MALARIA IS APPEARING SO THEY CAN DEPLOY APPROPRIATE RESOURCES TO HALT ITS SPREAD.PATH CONTINUED TO DEVELOP AND EVALUATE NEW VECTOR CONTROL TOOLS IN 2019 WITH OUR PARTNERS IN VECTORLINK, THE US AGENCY FOR INTERNATIONAL DEVELOPMENT'S (USAID'S) FLAGSHIP VECTOR CONTROL PROJECT. SIMILARLY, UNDER THE NEW NETS PROJECT FUNDED BY UNITAID AND THE GLOBAL FUND, WE HELPED GENERATE EVIDENCE FOR THE ADOPTION OF BEDNETS EFFECTIVE AGAINST PYRETHROID-RESISTANT MOSQUITOES. AND WE CONTINUED TO DEVELOP AND EVALUATE ATTRACTIVE TARGETED SUGAR BAITS, WHICH LURE MOSQUITOES TO A MEAL LACED WITH INSECTICIDE.IN 2019, THE MALARIA TEAM PARTNERED WITH PATH'S DIAGNOSTICS PROGRAM ON EVALUATIONS OF RAPID TESTS FOR MALARIA AS WELL AS CLINICAL STUDIES FOR POINT-OF-CARE TESTS TO DETECT AN ENZYME DEFICIENCY THAT CAN COMPLICATE TREATMENT OF PLASMODIUM VIVAX MALARIA. PATH ALSO SUPPORTED THE COMMERCIALIZATION OF A DIAGNOSTICS ARRAY THAT CAN BE USED FOR MALARIA RESEARCH AND SURVEILLANCE. MOREOVER, WE LED A VALIDATION OF THE RESULTS OF MALARIA TESTS TAKEN DURING ANTENATAL CARE AS A ROUTINE MEASURE OF PARASITE PREVALENCE. FOR MORE INFORMATION, SEE THE DIAGNOSTICS SECTION. FINALLY, PATH WORKED WITH THE WORLD HEALTH ORGANIZATION (WHO) AND OTHER PARTNERS, INCLUDING THE MINISTRIES OF HEALTH IN GHANA, KENYA, AND MALAWI, TO INTRODUCE THE WORLD'S FIRST MALARIA VACCINE, KNOWN AS RTS,S, IN SELECTED AREAS OF THOSE COUNTRIES.PATH'S EFFORTS TO ELIMINATE NEGLECTED TROPICAL DISEASES CONTINUED IN 2019 IN THE DEMOCRATIC REPUBLIC OF THE CONGO (DRC), WHERE WE WORKED WITH THE COUNTRY'S NATIONAL PROGRAM TO COMBAT HUMAN AFRICAN TRYPANOSOMIASIS (HAT, OR "SLEEPING SICKNESS"). WE SUPPORTED THE PROGRAM IN ACTIVE AND PASSIVE SCREENING FOR HAT CASES IN THREE KEY PROVINCES, AND WE ASSISTED THE LIVERPOOL SCHOOL OF TROPICAL MEDICINE TO DEPLOY CONTROL MEASURES FOR THE HAT VECTOR, TSETSE FLIES, USING THE "TINY TARGET" INNOVATIVE TECHNOLOGY. OUR WORK ALSO INCLUDED ADVOCACY TO RAISE AWARENESS OF HAT AT NATIONAL, PROVINCIAL, AND COMMUNITY LEVELS.IN INDIA, PATH CONTINUED TO PROVIDE STRATEGIC TECHNICAL ASSISTANCE AT THE NATIONAL, STATE (UTTAR PRADESH), AND SUB-STATE LEVELS FOR ELIMINATION OF VISCERAL LEISHMANIASIS (KALA-AZAR) AND LYMPHATIC FILARIASIS (ELEPHANTIASIS). ADDITIONALLY, WE SUPPORTED INDIA'S VECTOR-BORNE DISEASE CONTROL PROGRAM AT THE STATE LEVEL TO COMBAT MALARIA, DENGUE, AND CHIKUNGUNYA.HIV AND TUBERCULOSIS:IN 2019, PATH CONTINUED CONTRIBUTIONS TO HIV PREVENTION AND EPIDEMIC CONTROL, AS WELL AS TUBERCULOSIS (TB) DETECTION AND CONTROL. OUR PROGRAMMING REACHED GENERAL POPULATIONS AS WELL AS THE KEY POPULATIONS OF ADOLESCENT GIRLS AND YOUNG WOMEN, PEOPLE WITH BOTH HIV AND TB, SEX WORKERS AND THEIR CLIENTS, MEN WHO HAVE SEX WITH MEN, PEOPLE WHO INJECT DRUGS, AND TRANSGENDER INDIVIDUALS. WE CONTINUED TO FIND AND DIAGNOSE, LINK TO TREATMENT, AND RETAIN PEOPLE ON TREATMENT AS WE ADVANCED PROGRAMMING ACROSS TECHNOLOGY AND SERVICE DELIVERY PLATFORMS. PATH SCALED DIFFERENTIATED PARTNER NOTIFICATION SERVICES, PROVIDING NEWLY DIAGNOSED PEOPLE LIVING WITH HIV (PLHIV) WITH A SUITE OF OPTIONS FOR DISCLOSING THEIR POSITIVE STATUS AND PROVIDING HIV TESTING SERVICES TO THEIR PARTNERS AND FAMILIES. ACROSS OUR USAID-FUNDED PROGRAMS IN THE DRC, KENYA, UKRAINE, AND VIETNAM, WE TESTED MORE THAN 744,775 PEOPLE, INCLUDING 48,366 PARTNERS AND FAMILY MEMBERS OF PLHIV, AND ENROLLED MORE THAN 24,680 NEWLY DIAGNOSED PLHIV ON TREATMENT. AMBASSADOR DEBORAH BIRX HIGHLIGHTED OUR APPROACH AS THE MODEL THAT ALL COUNTRIES INVOLVED IN THE US PRESIDENT'S EMERGENCY PLAN FOR AIDS RELIEF (PEPFAR) SHOULD FOLLOW. OUR APPROACH ALSO LED TO A COLLABORATION WITH WHO TO DEVELOP GLOBAL GUIDELINES FOR SAFE PARTNER NOTIFICATION SERVICES FOR SEX WORKERS.IN THE DRC, PATH CONTINUED TO LEAD USAID-FUNDED EFFORTS TO CONTROL THE HIV EPIDEMIC. IN 2019, THIS WORK FOCUSED ON TWO HIGH-PREVALENCE PROVINCES UNDER THE INTEGRATED HIV/AIDS PROJECT IN HAUT-KATANGA/LUALABA. PATH PROVIDED TECHNICAL ASSISTANCE TO 162 HEALTH FACILITIES, 18 HEALTH ZONES, AND FIVE NONGOVERNMENTAL ORGANIZATIONS (NGOS) TO INCREASE TARGETED TESTING EFFORTS, ENROLL ALL IDENTIFIED HIV-POSITIVE INDIVIDUALS ON TREATMENT, PROVIDE VIRAL LOAD TESTING, AND ROLL OUT DIFFERENTIATED CARE MODELS. PATH TESTED APPROXIMATELY 250,000 PEOPLE IN THE DRC, LINKED AROUND 14,000 NEWLY IDENTIFIED PLHIV TO TREATMENT, AND SUPPORTED A COHORT OF 40,000 PEOPLE TO CONTINUE TREATMENT. THROUGH THE AIDS, POPULATION, AND HEALTH INTEGRATED ASSISTANCE PROGRAM PLUS (APHIAPLUS) PROJECT IN 2019, PATH OPERATIONALIZED ELECTRONIC MEDICAL RECORDS SYSTEMS AT HEALTH FACILITIES IN WESTERN KENYA. BUILDING ON APHIAPLUS, WE ALSO LED THE USAID AND PEPFAR-FUNDED AFYA ZIWANI PROJECT. WE TESTED APPROXIMATELY 500,000 PEOPLE FOR HIV, LINKED AROUND 8,000 NEWLY IDENTIFIED PLHIV TO TREATMENT, AND SUPPORTED A COHORT OF 50,000 PEOPLE TO CONTINUE TREATMENT. TO DO THIS, WE DEVELOPED INNOVATIVE TOOLS FOR ELIGIBILITY SCREENING AND TRACKING MISSED APPOINTMENTS, AS WELL AS DATA DASHBOARDS. ALSO AS PART OF AFYA ZIWANI, PATH IMPLEMENTED THE DREAMS INITIATIVE, INTENSIFYING EFFORTS TO REACH NEARLY 80,000 ADOLESCENT GIRLS AND YOUNG WOMEN IN KENYA WITH INTERVENTIONS TO REDUCE THEIR VULNERABILITY TO HIV AND IMPROVE THEIR ACCESS TO SERVICES. | Desc |
Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $85,821,408 | ExpenseAmt |
| Grant | $27,113,038 | GrantAmt |
| Revenue | $1,000 | RevenueAmt |
| Desc | ESSENTIAL MEDICINES: PATH'S ESSENTIAL MEDICINES DIVISION DEVELOPS AND DELIVERS LIFESAVING VACCINES AND DRUGS FOR WOMEN, CHILDREN, AND COMMUNITIES AROUND THE GLOBE. (CONTINUED ON SCHEDULE O)CENTER FOR VACCINE INNOVATION AND ACCESSPATH'S CENTER FOR VACCINE INNOVATION AND ACCESS (CVIA) ALIGNS EXPERTISE ACROSS EVERY STAGE OF VACCINE RESEARCH, DEVELOPMENT, AND INTRODUCTION TO MAKE VACCINES AVAILABLE TO MORE COMMUNITIES, PARTICULARLY IN LOW- AND MIDDLE-INCOME COUNTRIES. OUR PORTFOLIO INCLUDES MORE THAN TWO DOZEN VACCINE PRODUCTS IN DEVELOPMENT OR ALREADY IN USE, WITH AN EMPHASIS ON THE LEADING INFECTIOUS CAUSES OF CHILD DEATH AND DISEASE WORLDWIDE.FOR EXAMPLE, IN 2019 PATH CONTINUED TO PARTNER WITH COUNTRIES TO EXPAND COVERAGE OF JAPANESE ENCEPHALITIS (JE) VACCINATION AND CARRIED OUT A CAMPAIGN TO CELEBRATE PROGRESS TOWARD COMBATING JE. THE GOVERNMENT OF THE PHILIPPINES CONDUCTED JE VACCINATION CAMPAIGNS IN FOUR HIGH-RISK PROVINCES, WHICH PATH SUPPORTED THROUGH PLANNING, VACCINE PROVISION, AND COST-EFFECTIVENESS ANALYSIS. AS PATH'S 16-YEAR GLOBAL JE PARTNERSHIP PREPARED TO CLOSE, WE HOSTED A MEETING WITH KEY STAKEHOLDERS IN HANOI TO DISCUSS AND CAPTURE LESSONS LEARNED FOR COUNTRY VACCINATION PROGRAMS AND INTERNATIONAL VACCINE PARTNERS. PATH DEVELOPED AND LAUNCHED A WEB PAGE, INFOGRAPHIC, AND REPORT OUTLINING THESE LESSONS AND THE STORY OF JE VACCINATION EFFORTS. ALSO IN 2019, WE BEGAN A PIVOTAL, PHASE 3 STUDY OF A POLYVALENT MENINGOCOCCAL MENINGITIS VACCINE. THE VACCINE, DEVELOPED BY SERUM INSTITUTE OF INDIA PVT. LTD., BUILDS ON THE SUCCESS OF MENAFRIVAC, A VACCINE AGAINST MENINGOCOCCAL MENINGITIS SEROGROUP A THAT WAS LICENSED AND INTRODUCED IN 2010. THE POLYVALENT VACCINE TARGETS SEROGROUPS A, C, W, X, AND Y. THE VACCINE IS DESIGNED FOR USE IN AFRICA'S "MENINGITIS BELT" REGION AND, AS THE FIRST VACCINE TO TARGET SEROGROUP X, HAS THE POTENTIAL TO ELIMINATE MENINGITIS EPIDEMICS FROM THIS REGION. TO PREVENT MALARIA, PATH IS ACCELERATING THE DEVELOPMENT OF A WIDE VARIETY OF MALARIA VACCINE CANDIDATES AND APPROACHES. IN 2019, WE WORKED WITH WHO AND OTHER PARTNERS, INCLUDING THE MINISTRIES OF HEALTH IN GHANA, KENYA, AND MALAWI, TO BEGIN PILOT IMPLEMENTATION OF THE RTS,S VACCINE IN SELECTED AREAS OF THOSE COUNTRIES. WITH OUR PARTNERS, PATH CONTINUED TO ADVANCE RESEARCH INTO WHETHER REDUCING THE DOSE LEVEL OF RTS,S AND DELAYING THE ADMINISTRATION OF DOSES HAS THE POTENTIAL TO FURTHER AID MALARIA ELIMINATION EFFORTS BY STRETCHING LIMITED VACCINE SUPPLIES AND PROTECTING AS MANY PEOPLE AS POSSIBLE. PILOT INTRODUCTION IN KENYA OF THE DELAYED FRACTIONAL-DOSE REGIMEN BEGAN IN 2019. ADDITIONALLY, WORK CONTINUED ON EFFORTS TO IDENTIFY IMMUNE CORRELATES OF PROTECTION FOR MALARIA VACCINES AND ON THE USE OF MONOCLONAL ANTIBODIES TO COMBAT MALARIA.IN 2019, THE DEFEAT DIARRHEAL DISEASE (DEFEATDD) INITIATIVE, HOUSED WITHIN CVIA, CONTINUED ITS ROLE AS A DIGITAL HUB FOR KEY INFORMATION AROUND PREVENTING AND TREATING CHILDHOOD DIARRHEAL DISEASE. IN PARTNERSHIP WITH PATH'S DRUG DEVELOPMENT PROGRAM, DEFEATDD LAUNCHED A CAMPAIGN TO PROMOTE THE ADDITION OF CO-PACKAGED ORAL REHYDRATION SOLUTION (ORS) AND ZINC TO THE WHO ESSENTIAL MEDICINES LIST FOR CHILDREN. DEFEATDD ALSO LAUNCHED A CAMPAIGN FOR WORLD TOILET DAY AROUND THE ROLE OF SANITATION IN HEALTH CARE ALONGSIDE VACCINES, NUTRITION, AND ACCESS TO MEDICINES. THROUGHOUT THE YEAR, DEFEATDD'S CHANNELS HELPED DISSEMINATE POLICY UPDATES AND RESEARCH ON THE PROJECTED HEALTH AND ECONOMIC IMPACTS OF NEW AND EXISTING ENTERIC VACCINES, INCLUDING ROTAVIRUS, CHOLERA, ENTEROTOXIGENIC ESCHERICHIA COLI, SHIGELLA, AND TYPHOID. DEFEATDD ALSO MAINTAINED, UPDATED, AND EXPANDED UPON ITS ONLINE STATE-OF-THE-FIELD REPORT, STOP THE CYCLE OF DIARRHEA. PATH CONDUCTED A PHASE 3 BRIDGING STUDY IN VIETNAM TO COMPARE A NEW LIQUID FORMULATION OF THE ROTAVIRUS VACCINE, ROTAVIN, WITH AN EARLIER LICENSED FROZEN FORMULATION, ROTAVIN-M1. WE CONDUCTED A PHASE 1 STUDY IN THE UNITED STATES TO ASSESS THE SAFETY OF A SUBUNIT SHIGELLA VACCINE CANDIDATE. ADDITIONALLY, PATH HELPED INTRODUCE AND ADVANCE ACCESS TO CURRENTLY AVAILABLE ENTERIC VACCINES, INCLUDING THE RECENTLY WHO-PREQUALIFIED ROTAVAC AND ROTASIIL ROTAVIRUS VACCINES.TO PREVENT TYPHOID, PATH, AS PART OF THE TYPHOID VACCINE ACCELERATION CONSORTIUM, IS WORKING TO ACCELERATE INTRODUCTION OF TYPHOID CONJUGATE VACCINES (TCVS) IN LOW-INCOME COUNTRIES. IN 2019, PATH SUPPORTED COUNTRIES THROUGHOUT THE VACCINE DECISION-MAKING AND INTRODUCTION PROCESS. WITH SUPPORT FROM PATH, PAKISTAN BECAME THE FIRST COUNTRY TO INTRODUCE TCV INTO ITS ROUTINE CHILDHOOD IMMUNIZATION PROGRAM. WE ALSO WORKED WITH THE GOVERNMENTS OF LIBERIA AND ZIMBABWE TO DETERMINE APPROPRIATE TCV INTRODUCTION STRATEGIES, SUCCESSFULLY APPLY FOR GAVI FINANCING, AND PREPARE FOR TCV INTRODUCTION. PATH CONTINUED TO CALL ATTENTION TO TYPHOID AND THE NEED FOR INTEGRATED SOLUTIONS THROUGH A RANGE OF ADVOCACY AND COMMUNICATIONS ACTIVITIES. PATH CONTINUED TO ADVANCE PRECLINICAL DEVELOPMENT OF A VACCINE AGAINST GROUP B STREPTOCOCCUS, THE LEADING CAUSE OF BACTERIAL SEPSIS AND MENINGITIS IN YOUNG INFANTS WORLDWIDE. PATH IS SUPPORTING INVENTPRISE, A BIOTECHNOLOGY COMPANY, AS IT WORKS TO DEVELOP A MULTIVALENT, CONJUGATE VACCINE FOR LOW- AND MIDDLE-INCOME COUNTRIES. THE INTENDED RECIPIENTS ARE PREGNANT WOMEN-PART OF A STRATEGY THAT BOOSTS IMMUNITY AGAINST THE BACTERIUM AND TRANSFERS PROTECTIVE ANTIBODIES TO THE DEVELOPING BABY. ALSO IN 2019, PATH CONTINUED TO COORDINATE A CONSORTIUM OF NINE INDEPENDENT RESEARCH INSTITUTIONS TO ANALYZE EVIDENCE ON THE POTENTIAL FOR SINGLE-DOSE HPV VACCINATION. ALTHOUGH MANY COUNTRIES HAVE INTRODUCED HPV VACCINES INTO THEIR NATIONAL IMMUNIZATION SCHEDULES, SOME HAVE DELAYED INTRODUCTION BECAUSE OF FINANCIAL, LOGISTICAL, OR OTHER BARRIERS. FOR THESE COUNTRIES, A SINGLE-DOSE REGIMEN COULD ACCELERATE INTRODUCTION. PATH PROVIDES TECHNICAL ASSISTANCE TO GAVI-ELIGIBLE COUNTRIES IN PLANNING, IMPLEMENTING, AND EVALUATING NATIONAL HPV VACCINATION PROGRAMS AIMED AT VACCINATING YOUNG WOMEN. IN 2019, OUR GLOBAL TEAM AND PARTNERS ASSISTED THE GAMBIA, KENYA, AND THE SOLOMON ISLANDS WITH NATIONAL INTRODUCTIONS. | Desc |
Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $27,230,902 | ExpenseAmt |
| Grant | $4,675,897 | GrantAmt |
| Revenue | $1,000 | RevenueAmt |
| Desc | TECHNOLOGY, ANALYTICS, AND MARKET INNOVATION: PATH'S TECHNOLOGY, ANALYTICS, AND MARKET INNOVATION (TAMI) DIVISION IS AN INTEGRATED GLOBAL PLATFORM FOR END-TO-END ADVANCEMENT OF HIGH-IMPACT MEDICAL DEVICES, HEALTH TECHNOLOGIES, DIAGNOSTICS, AND IN-COUNTRY "IMPACT LABS" THAT ADDRESS GLOBAL, REGIONAL, AND COUNTRY HEALTH NEEDS. TAMI ALSO MANAGES PATH'S WORK IN MARKET DYNAMICS AND DIGITAL AND DATA EXCELLENCE.(CONTINUED ON SCHEDULE O)MEDICAL DEVICES AND HEALTH TECHNOLOGIES:THE MEDICAL DEVICES AND HEALTH TECHNOLOGIES PROGRAM WITHIN TAMI IS PATH'S INNOVATIVE PRODUCT DEVELOPMENT ARM. THE PROGRAM WORKS WITH PUBLIC- AND PRIVATE-SECTOR PARTNERS AROUND THE WORLD TO DEVELOP, TEST, REFINE, INTRODUCE, AND SCALE AFFORDABLE TECHNOLOGIES TO IMPROVE THE HEALTH OF PEOPLE IN LOW- AND MIDDLE-INCOME COUNTRIES.IN 2019, THE PROGRAM REACHED SEVERAL KEY MILESTONES; FOR EXAMPLE, THE ELLAVI UTERINE BALLOON TAMPONADE, A MEDICAL PRODUCT ADVANCED BY PATH TO MANAGE POSTPARTUM HEMORRHAGE, RECEIVED A CE MARK, AND THE FIRST SOLAR-POWERED "ENERGY HARVESTING CONTROL" VACCINE REFRIGERATORS, FOR WHICH PATH HAS BEEN CONDUCTING IN-COUNTRY ASSESSMENTS, PASSED PREQUALIFICATION TESTING IN SENEGAL FOR WHO PERFORMANCE, QUALITY, AND SAFETY APPROVAL. (ENERGY HARVESTING CONTROL ALLOWS EXTRA SOLAR POWER TO BE USED FOR OTHER PURPOSES AT A HEALTH FACILITY.) IN ADDITION, WE TRANSFERRED A FORMULATION AND LYOPHILIZATION PROCEDURE TO DERMBIONT FOR A TOPICAL GEL FORMULATION OF JANTHINOBACTERIUM LIVIDUM BACTERIA FOR TREATING FUNGAL INFECTIONS.PATH ALSO WORKED IN 2019 TO EVALUATE AND ADVANCE DEVICES FOR LONG-TERM ANTIRETROVIRAL DELIVERY OF PREP AND HIV TREATMENT. THESE DEVICES INCLUDE MICROARRAY PATCHES FOR TRANSDERMAL DELIVERY. STAFF PRODUCED 17 JOURNAL ARTICLES AND REPORTS ON RESEARCH FINDINGS, INCLUDING 2 FOR INACTIVATED POLIOVIRUS VACCINE: ONE EVALUATING THE TECHNICAL PRODUCT ATTRIBUTES OF AN ORAL ENTERIC VACCINE CURRENTLY UNDER DEVELOPMENT FOR INFANTS, THE OTHER EVALUATING THE COST PER CHILD VACCINATED WITH FULL VERSUS FRACTIONAL-DOSE VACCINE.DIAGNOSTICS:PATH ADVANCES EQUITABLE AND SUSTAINABLE ACCESS TO QUALITY-ASSURED, PURPOSE-DRIVEN DIAGNOSTICS FOR BETTER TESTING AND TREATMENT OF DISEASES IN LOW-RESOURCE SETTINGS.IN 2019, OUR PIONEERING WORK IN DIAGNOSTICS INCLUDED QUALIFYING, VALIDATING, EVALUATING, AND COMMERCIALIZING TESTS, REFERENCE ASSAYS, AND TOOLS; CONDUCTING PERFORMANCE EVALUATIONS AND CLINICAL TRIALS TO INFORM PATIENT CARE; AND PUBLISHING 20 PEER-REVIEWED JOURNAL ARTICLES.IN PARTNERSHIP WITH PATH'S MALARIA AND NEGLECTED TROPICAL DISEASES PROGRAM, THE DIAGNOSTICS TEAM INITIATED SIX CLINICAL STUDIES FOR POINT-OF-CARE TESTS FOR GLUCOSE-6-PHOSPHATE DEHYDROGENASE (G6PD) DEFICIENCY, A CONDITION THAT CAN COMPLICATE TREATMENT OF PLASMODIUM VIVAX MALARIA. BY THE END OF 2019, WE HAD COMPLETED ENROLLMENT IN FIVE OF THE STUDIES. PATH ALSO SUPPORTED COMMERCIALIZATION OF THE QUANSYS Q-PLEX HUMAN MALARIA ARRAY, WHICH CAN BE USED FOR MALARIA RESEARCH AND SURVEILLANCE. ADDITIONALLY, WE EVALUATED THE PERFORMANCE OF SEVERAL MALARIA RAPID DIAGNOSTIC TESTS, WHICH CAN NOW PROCEED TO CLINICAL EVALUATIONS. THE DIAGNOSTICS TEAM ALSO ESTABLISHED A COMMUNITY OF PRACTICE FOR G6PD OPERATIONAL RESEARCH AND HOSTED THREE INFORMATION-SHARING WEBINARS. IN PARTNERSHIP WITH THE UNIVERSITY OF WASHINGTON, PATH DEVELOPED AND COMMERCIALIZED A BAG-MEDIATED FILTRATION SYSTEM FOR THE ENVIRONMENTAL SURVEILLANCE OF WILD POLIOVIRUS IN SEWAGE. THIS SYSTEM SIMPLIFIES COLLECTION OF THE MATERIAL TO BE TESTED. IN 2019, THE DIAGNOSTICS TEAM CELEBRATED THE LAUNCH OF AN ENZYME-LINKED IMMUNOSORBENT ASSAY KIT THAT WE HELPED DEVELOP AND EVALUATE TO DETECT EXPOSURE TO ONCHOCERCA VOLVULUS, THE PARASITE THAT CAUSES ONCHOCERCIASIS (RIVER BLINDNESS). THE KIT SUPPORTS SEROLOGICAL SURVEILLANCE FOR RIVER BLINDNESS IN CONTROL AND ELIMINATION PROGRAMS IN AFRICA.PATH DIAGNOSTICS ALSO QUALIFIED AND VALIDATED A REFERENCE ASSAY FOR LIPOARABINOMANNAN (LAM), A VIRULENCE FACTOR ASSOCIATED WITH TB. THIS REFERENCE ASSAY IS NOW AVAILABLE FOR THE TB DIAGNOSTIC COMMUNITY TO INDEPENDENTLY EVALUATE EMERGING DIAGNOSTIC LATERAL FLOW ASSAYS FOR THE DETECTION OF URINARY LAM. FURTHER, PATH COMPLETED A FIELD PERFORMANCE EVALUATION STUDY OF A NEW PREECLAMPSIA TEST WITH PARTNERS IN GHANA. AN AFRICAN-BASED MANUFACTURER LAUNCHED THE PRODUCT IN LATE 2019. IT IS NOW BEING USED TO INFORM PATIENT CARE. FINALLY, IN COLLABORATION WITH A PRIVATE-SECTOR PARTNER, PATH WORKED TO DEVELOP A SEROTYPE-SPECIFIC URINE ANTIGEN DETECTION ASSAY ON A PLATFORM SUITABLE FOR USE IN LOW- AND MIDDLE-INCOME COUNTRIES. THE ASSAY PROVIDES HIGH-PERFORMANCE DETECTION ACROSS AN EXPANDED PANEL OF COMMON PNEUMOCOCCAL CONJUGATED VACCINE SEROTYPES. THIS ENHANCED CAPACITY INCREASES ITS UTILITY AS A TOOL FOR BOTH CLINICAL AND EPIDEMIOLOGIC STUDIES TO SUPPORT DEVELOPMENT OF A PNEUMONIA VACCINE.IMPACT LABS:PATH'S IMPACT LABS IN INDIA AND SOUTH AFRICA HELP ADVANCE THE MOST PROMISING HEALTH TECHNOLOGIES. THESE COUNTRIES HAVE RICH INNOVATION ECOSYSTEMS WITH UNIVERSITIES, PRIVATE-SECTOR FIRMS, AND A GROWING NUMBER OF ENTREPRENEURS FOCUSED ON DEVELOPING PRODUCTS AND SERVICES THAT MAKE HEALTH CARE MORE AFFORDABLE, ACCESSIBLE, AND EFFECTIVE.THE INDIA IMPACT LAB, A PARTNERSHIP WITH TATA TRUSTS AND THE INDIAN INSTITUTE OF TECHNOLOGY DELHI, IS A PLATFORM TO ENABLE LATE-STAGE MEDICAL TECHNOLOGY (MEDTECH) INNOVATIONS TO ACHIEVE MARKET ENTRY, ADOPTION, AND SCALE. THE IMPACT LAB ALSO PARTNERS WITH TOP INDIAN TECHNOLOGY AND BUSINESS INCUBATORS IN THE LIFE SCIENCE AND HEALTH CARE INDUSTRIES TO FURTHER DEVELOP THE INNOVATION ECOSYSTEM. IN 2019, THE IMPACT LAB BEGAN ENGAGEMENT WITH TEN SELECTED MEDTECH START-UPS UNDER THE QUEST FOR HEALTHCARE INNOVATIONS PROGRAM, A JOINT INITIATIVE WITH SOCIAL ALPHA. THE PROGRAM FEATURES A SYSTEMATIC, COHORT-BASED ENGAGEMENT MODEL, PROVIDING THE SELECTED START-UPS WITH CONTEXTUAL SUPPORT, GUIDANCE, AND MENTORSHIP IN PRODUCT DEVELOPMENT, CLINICAL EVIDENCE GENERATION, REGULATIONS, QUALITY MANAGEMENT, MARKET UNDERSTANDING, AND PROCUREMENT CHANNELS. ACTIVITIES INCLUDED A DEEP AND EXPANSIVE REQUIREMENT MAPPING FOR EACH START-UP AS WELL AS SUPPORT FOR THEIR CLINICAL VALIDATION JOURNEY AND GO-TO-MARKET NEEDS. THE IMPACT LAB CONDUCTED TWO CURATED CONVENINGS FOR THE COHORT: ONE WITH DOMAIN EXPERTS IN CLINICAL AND REGULATORY COMPLIANCE, THE OTHER WITH EXPERTS IN PUBLIC AND PRIVATE MEDICAL DEVICE TECHNOLOGY ASSESSMENT AND PROCUREMENT. ADDITIONALLY, THE IMPACT LAB DELIVERED FIVE FOCUSED KNOWLEDGE PLATFORMS, INCLUDING WORKSHOPS AND ROUNDTABLES FOR THE WIDER MEDTECH ECOSYSTEM. FOR THESE, THE IMPACT LAB ENGAGED WITH EXPERTS FROM NUMEROUS LARGE AND SMALL MEDTECH COMPANIES, PARTNER INCUBATORS, INDUSTRY, AND ACADEMIA, AS WELL AS KEY NATIONAL AND GLOBAL STAKEHOLDERS. THE KNOWLEDGE PLATFORMS COVERED A RANGE OF TOPICS-FROM TESTING AND CALIBRATING MEDICAL DEVICES TO MEDTECH REGULATIONS, LATE-STAGE PRODUCT DEVELOPMENT, AND MARKET ACCESS- AND INCLUDED ROUNDTABLE DISCUSSION OF PERTINENT ISSUES IN TB DETECTION, TREATMENT, AND ADHERENCE TO MEDICATION. THE IMPACT LAB, A CROSS-CUTTING INITIATIVE WITHIN PATH, PROVIDED SUPPORT TO PATH'S PROGRAM VERTICALS, FOR EXAMPLE IN THE DEVELOPMENT OF A MENSTRUAL HEALTH APPLICATION FOR WOMEN IN LOW- AND MIDDLE-INCOME COUNTRIES, DEVELOPMENT OF A TARGET PRODUCT PROFILE FOR MICROARRAY PATCHES FOR RABIES VACCINE DELIVERY, AND OPERATIONAL VALIDATION OF TRUENAT, A MOLECULAR DIAGNOSTIC DEVICE FOR DETECTION OF TB. THROUGH THE SOUTH AFRICA IMPACT LAB, PATH ACCELERATED OUR ASSISTANCE TO THE SOUTH AFRICAN MEDICAL RESEARCH COUNCIL (SAMRC) THROUGH THE JOINT GLOBAL HEALTH INNOVATION ACCELERATOR (GHIA) PARTNERSHIP. GHIA, WHICH IS PRIMARILY FUNDED BY A GRANT FROM THE BILL & MELINDA GATES FOUNDATION TO SAMRC, CONTINUES TO SUPPORT THE DEVELOPMENT AND COMMERCIALIZATION OF MEDICAL TECHNOLOGIES DESIGNED FOR RESOURCE-LIMITED SETTINGS IN SOUTH AFRICA AND BEYOND. IN 2019, PATH HOSTED STAFF FROM SAMRC FOR A WEEKLONG EXCHANGE IN SEATTLE, WASHINGTON. THE FOCUS WAS ON SHARING INTERNAL PATH PROCESSES FOR TECHNOLOGY EVALUATION, PRODUCT DEVELOPMENT, AND GO-TO-MARKET STRATEGIES, AND IDENTIFYING AREAS OF SUPPORT ON CERTAIN GHIA PROJECTS. ADDITIONAL CAPACITY-BUILDING EFFORTS INCLUDED A "BOOTCAMP" SESSION IN CAPE TOWN TO DISCUSS PRODUCT INTRODUCTION TOPICS SUCH AS PROCUREMENT, MARKET SIZING, AND COUNTRY DOWN-SELECTION APPROACHES. TO INCREASE GHIA'S VISIBILITY, PATH AND SAMRC CO-WROTE AND PUBLISHED AN ARTICLE REFLECTING ON THE LAST FIVE YEARS. | Desc |
Prog Srvc Accom Acty Other ProgSrvcAccomActyOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $22,615,272 | ExpenseAmt |
| Grant | $4,940,809 | GrantAmt |
| Desc | ADVOCACY AND PUBLIC POLICYPATH'S ADVOCACY AND PUBLIC POLICY TEAM WORKS IN THE UNITED STATES, AT THE GLOBAL LEVEL WITH MULTILATERAL AGENCIES, AND IN COUNTRIES AND COMMUNITIES AROUND THE WORLD. WE HELP POLICYMAKERS UNDERSTAND ISSUES AND MOTIVATE THEM TO COMMIT FUNDING, CRAFT POLICIES, AND SPONSOR INITIATIVES TO STRENGTHEN GLOBAL HEALTH EFFORTS. IN 2019, PATH LED EFFORTS TO ENSURE SUPPORT AMONG POLICYMAKERS IN THE UNITED STATES, EUROPE, AND MULTILATERAL AGENCIES TO MAINTAIN AND STRENGTHEN WORK IN RESEARCH AND DEVELOPMENT (R&D), MATERNAL AND CHILD HEALTH, IMMUNIZATION, AND GLOBAL HEALTH SECURITY. OUR SUCCESSES IN 2019 INCLUDED PROTECTING KEY US GOVERNMENT FUNDING FOR OUR PRIORITY HEALTH AREAS AND SUCCESSFULLY INFLUENCING LANGUAGE CALLING FOR NEW R&D FUNDING AND STRONG REGULATORY SYSTEMS IN THE OUTCOME STATEMENT OF THE UNITED NATIONS HIGH-LEVEL MEETING ON UNIVERSAL HEALTH COVERAGE. WORKING WITH PARTNERS IN AFRICAN COUNTRIES, WE HELPED ADVANCE POLICIES TO IMPROVE THE HEALTH OF WOMEN AND CHILDREN. AMONG MANY ACHIEVEMENTS DURING 2019, IN THE DRC, A NATIONAL IMMUNIZATION FORUM WE ORGANIZED IN PARTNERSHIP WITH THE HEAD OF STATE LED TO AN UNPRECEDENTED COMMITMENT BY NATIONAL AND PROVINCIAL LEADERS TO IMPROVE ROUTINE IMMUNIZATION AND POLIO ERADICATION EFFORTS. IN UGANDA, PATH'S ONGOING IMMUNIZATION ADVOCACY RESULTED IN THE GOVERNMENT NEARLY DOUBLING ITS BUDGET FOR ROUTINE IMMUNIZATION. IN KENYA, YEARS OF ADVOCACY BY PATH RESULTED IN PASSAGE OF THE FIRST COMPREHENSIVE POLICY IDENTIFYING PRIORITIES FOR HEALTH R&D, AND IN SOUTH AFRICA, PATH'S ADVOCACY AND COALITION-BUILDING EFFORTS CONTINUED TO STRENGTHEN SUPPORT FOR HEALTH R&D.SPECIAL INITIATIVESPATH IS ENGAGED IN A VARIETY OF SPECIAL INITIATIVES THAT GALVANIZE OUR EXPERTISE AND RESOURCES AND THOSE OF OUR GLOBAL PARTNERS TO SAVE MORE LIVES, MORE QUICKLY. BY THE END OF 2019, WE HAD ACTIVE HEALTH IMPACT TEAMS IN SEVEN HEALTH AREAS. EACH HEALTH IMPACT TEAM HAS BEEN ONGOING FOR AT LEAST TWO YEARS, WORKING TO BUILD STRUCTURED COLLABORATION ACROSS PROGRAMS AND GEOGRAPHIES TO INCREASE PATH'S IMPACT. | Desc |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Other Prog Srvc Expense | $22,615,272 | TotalOtherProgSrvcExpenseAmt |
| Total Other Prog Srvc Grant | $4,940,809 | TotalOtherProgSrvcGrantAmt |
| Total Program Service Expenses | $257,713,007 | TotalProgramServiceExpensesAmt |
| Described In Section501c3 | Yes (1) | DescribedInSection501c3Ind |
| Schedule B Required | Yes (1) | ScheduleBRequiredInd |
| Political Campaign Acty | 0 | PoliticalCampaignActyInd |
| Lobbying Activities | Yes (1) | LobbyingActivitiesInd |
| Subject To Proxy Tax | 0 | SubjectToProxyTaxInd |
| Donor Advised Fund | 0 | DonorAdvisedFundInd |
| Conservation Easements | 0 | ConservationEasementsInd |
| Collections Of Art | 0 | CollectionsOfArtInd |
| Credit Counseling | 0 | CreditCounselingInd |
| Donor Rstr Or Quasi Endowments | Yes (1) | DonorRstrOrQuasiEndowmentsInd |
| Report Land Building Equipment | Yes (1) | ReportLandBuildingEquipmentInd |
| Report Investments Other Sec | 0 | ReportInvestmentsOtherSecInd |
| Report Program Related Invst | 0 | ReportProgramRelatedInvstInd |
| Report Other Assets | 0 | ReportOtherAssetsInd |
| Report Other Liabilities | 0 | ReportOtherLiabilitiesInd |
| Include FIN48 Footnote | 0 | IncludeFIN48FootnoteInd |
| Independent Audit Fincl Stmt | 0 | IndependentAuditFinclStmtInd |
| Consolidated Audit Fincl Stmt | Yes (1) | ConsolidatedAuditFinclStmtInd |
| School Operating | 0 | SchoolOperatingInd |
| Foreign Office | Yes (1) | ForeignOfficeInd |
| Foreign Activities | Yes (1) | ForeignActivitiesInd |
| More Than5000 K To Org | Yes (1) | MoreThan5000KToOrgInd |
| More Than5000 K To Individuals | 0 | MoreThan5000KToIndividualsInd |
| Professional Fundraising | 0 | ProfessionalFundraisingInd |
| Fundraising Activities | 0 | FundraisingActivitiesInd |
| Gaming Activities | 0 | GamingActivitiesInd |
| Operate Hospital | 0 | OperateHospitalInd |
| Grants To Organizations | Yes (1) | GrantsToOrganizationsInd |
| Grants To Individuals | Yes (1) | GrantsToIndividualsInd |
| Schedule J Required | Yes (1) | ScheduleJRequiredInd |
| Tax Exempt Bonds | 0 | TaxExemptBondsInd |
| Engaged In Excess Benefit Trans | 0 | EngagedInExcessBenefitTransInd |
| PY Excess Benefit Trans | 0 | PYExcessBenefitTransInd |
| Loan Outstanding | 0 | LoanOutstandingInd |
| Grant To Related Person | 0 | GrantToRelatedPersonInd |
| Business Rln With Org Mem | 0 | BusinessRlnWithOrgMemInd |
| Business Rln With Fam Mem | 0 | BusinessRlnWithFamMemInd |
| Business Rln With35 Ctrl Ent | 0 | BusinessRlnWith35CtrlEntInd |
| Deductible Non Cash Contri | Yes (1) | DeductibleNonCashContriInd |
| Deductible Art Contribution | 0 | DeductibleArtContributionInd |
| Terminate Operations | 0 | TerminateOperationsInd |
| Partial Liquidation | 0 | PartialLiquidationInd |
| Disregarded Entity | 0 | DisregardedEntityInd |
| Related Entity | Yes (1) | RelatedEntityInd |
| Related Organization Ctrl Ent | Yes (1) | RelatedOrganizationCtrlEntInd |
| Transaction With Control Ent | Yes (1) | TransactionWithControlEntInd |
| Trnsfr Exmpt Non Chrtbl Rltd Org | 0 | TrnsfrExmptNonChrtblRltdOrgInd |
| Activities Conducted Prtshp | 0 | ActivitiesConductedPrtshpInd |
| Schedule O Required | Yes (1) | ScheduleORequiredInd |
| Info In Schedule O Part V | Yes (X) | InfoInScheduleOPartVInd |
| IRP Document | 248 | IRPDocumentCnt |
| IRP Document W2 G | 0 | IRPDocumentW2GCnt |
| Backup Wthld Compliance | Yes (1) | BackupWthldComplianceInd |
| Employee | 737 | EmployeeCnt |
| Employment Tax Returns Filed | Yes (1) | EmploymentTaxReturnsFiledInd |
| Unrelated Bus Incm Over Limit | 0 | UnrelatedBusIncmOverLimitInd |
| Foreign Financial Account | Yes (1) | ForeignFinancialAccountInd |
| Foreign Country | BE | ForeignCountryCd |
| Foreign Country | CH | ForeignCountryCd |
| Foreign Country | CG | ForeignCountryCd |
| Foreign Country | ET | ForeignCountryCd |
| Foreign Country | GH | ForeignCountryCd |
| Foreign Country | IN | ForeignCountryCd |
| Foreign Country | KE | ForeignCountryCd |
| Foreign Country | BM | ForeignCountryCd |
| Foreign Country | MZ | ForeignCountryCd |
| Foreign Country | PE | ForeignCountryCd |
| Foreign Country | SG | ForeignCountryCd |
| Foreign Country | SF | ForeignCountryCd |
| Foreign Country | SZ | ForeignCountryCd |
| Foreign Country | TZ | ForeignCountryCd |
| Foreign Country | UG | ForeignCountryCd |
| Foreign Country | UK | ForeignCountryCd |
| Foreign Country | UP | ForeignCountryCd |
| Foreign Country | VM | ForeignCountryCd |
| Foreign Country | ZA | ForeignCountryCd |
| Prohibited Tax Shelter Trans | 0 | ProhibitedTaxShelterTransInd |
| Taxable Party Notification | 0 | TaxablePartyNotificationInd |
| Nondeductible Contributions | 0 | NondeductibleContributionsInd |
| Quid Pro Quo Contributions | 0 | QuidProQuoContributionsInd |
| Form8282 Property Disposed Of | 0 | Form8282PropertyDisposedOfInd |
| Rcv Fnds To Pay Prsnl Bnft Cntrct | 0 | RcvFndsToPayPrsnlBnftCntrctInd |
| Pay Premiums Prsnl Bnft Cntrct | 0 | PayPremiumsPrsnlBnftCntrctInd |
| Indoor Tanning Services | 0 | IndoorTanningServicesInd |
| Subj To Tax Rmnrtn Ex Prcht Pymt | 0 | SubjToTaxRmnrtnExPrchtPymtInd |
| Subject To Excs Tax Net Invst Inc | 0 | SubjectToExcsTaxNetInvstIncInd |
| Info In Schedule O Part VI | Yes (X) | InfoInScheduleOPartVIInd |
| Governing Body Voting Members | 15 | GoverningBodyVotingMembersCnt |
| Independent Voting Member | 15 | IndependentVotingMemberCnt |
| Family Or Business Rln | 0 | FamilyOrBusinessRlnInd |
| Delegation Of Mgmt Duties | 0 | DelegationOfMgmtDutiesInd |
| Change To Org Documents | 0 | ChangeToOrgDocumentsInd |
| Material Diversion Or Misuse | 0 | MaterialDiversionOrMisuseInd |
| Members Or Stockholders | 0 | MembersOrStockholdersInd |
| Election Of Board Members | 0 | ElectionOfBoardMembersInd |
| Decisions Subject To Approva | 0 | DecisionsSubjectToApprovaInd |
| Minutes Of Governing Body | Yes (1) | MinutesOfGoverningBodyInd |
| Minutes Of Committees | Yes (1) | MinutesOfCommitteesInd |
| Officer Mailing Address | 0 | OfficerMailingAddressInd |
| Local Chapters | 0 | LocalChaptersInd |
| Form990 Provided To Gvrn Body | Yes (1) | Form990ProvidedToGvrnBodyInd |
| Conflict Of Interest Policy | Yes (1) | ConflictOfInterestPolicyInd |
| Annual Disclosure Covered Prsn | Yes (1) | AnnualDisclosureCoveredPrsnInd |
| Regular Monitoring Enfrc | Yes (1) | RegularMonitoringEnfrcInd |
| Whistleblower Policy | Yes (1) | WhistleblowerPolicyInd |
| Document Retention Policy | Yes (1) | DocumentRetentionPolicyInd |
| Compensation Process CEO | Yes (1) | CompensationProcessCEOInd |
| Compensation Process Other | Yes (1) | CompensationProcessOtherInd |
| Investment In Joint Venture | 0 | InvestmentInJointVentureInd |
| States Where Copy Of Return Is Fld | AL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | AR | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | CA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | CT | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | FL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | IL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | KS | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | KY | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MD | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MN | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MS | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NC | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NH | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NJ | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NM | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NY | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | OK | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | OR | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | PA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | RI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | SC | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | TN | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | UT | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | VA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | WI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | WV | StatesWhereCopyOfReturnIsFldCd |
| Own Website | Yes (X) | OwnWebsiteInd |
| Upon Request | Yes (X) | UponRequestInd |
Books In Care Of Detail BooksInCareOfDetail
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | BRIAN NEVILLE VP ACCOUNTINGFINANCIAL OPERATIONS | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Phone | 2062853500 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 2201 WESTLAKE AVE SUITE 200 | AddressLine1Txt |
| City | SEATTLE | CityNm |
| State Abbreviation | WA | StateAbbreviationCd |
| ZIP | 98121 | ZIPCd |
Form990 Part VII Section A Form990PartVIISectionAGrp (32 entries)
| TitleTitleTxt | Average Hours Per WeekAverageHoursPerWeekRt | Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd | OfficerOfficerInd | Reportable Comp From OrgReportableCompFromOrgAmt | Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt | Other CompensationOtherCompensationAmt | Average Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRt | Key EmployeeKeyEmployeeInd | Highest Compensated EmployeeHighestCompensatedEmployeeInd |
|---|---|---|---|---|---|---|---|---|---|
| DAVID KING | |||||||||
| CHAIR | 2.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | |||
| BETH GALETTI | |||||||||
| VICE CHAIR | 2.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | |||
| YEHONG ZHANG | |||||||||
| SECRETARY | 2.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | |||
| BRUCE MCNAMER | |||||||||
| TREASURER | 2.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | |||
| FELIX OLALE | |||||||||
| DIRECTOR | 2.00 | Yes (X) | $0 | $0 | $0 | ||||
| JO ADDY | |||||||||
| DIRECTOR | 2.00 | Yes (X) | $0 | $0 | $0 | ||||
| IREENA VITTAL | |||||||||
| DIRECTOR | 2.00 | Yes (X) | $0 | $0 | $0 | ||||
| DEANNA OPPENHEIMER | |||||||||
| DIRECTOR | 2.00 | Yes (X) | $0 | $0 | $0 | ||||
| JOHN-ARNE ROTTINGEN | |||||||||
| DIRECTOR | 2.00 | Yes (X) | $0 | $0 | $0 | ||||
| JOEL HOLSINGER | |||||||||
| DIRECTOR | 2.00 | Yes (X) | $0 | $0 | $0 | ||||
| HELENA WAYTH | |||||||||
| DIRECTOR | 2.00 | Yes (X) | $0 | $0 | $0 | ||||
| SANFORD MELZER | |||||||||
| DIRECTOR | 2.00 | Yes (X) | $0 | $0 | $0 | ||||
| ABAYOMI SULE | |||||||||
| DIRECTOR (BEGAN 6/2019) | 2.00 | Yes (X) | $0 | $0 | $0 | ||||
| LISA ANDERSON | |||||||||
| DIRECTOR (BEGAN 6/2019) | 2.00 | Yes (X) | $0 | $0 | $0 | ||||
| RACHEL SIBANDE | |||||||||
| DIRECTOR (BEGAN 6/2019) | 2.00 | Yes (X) | $0 | $0 | $0 | ||||
| STEPHEN BROWN DAVIS | |||||||||
| PRESIDENT AND CEO | 39.00 | Yes (X) | $560,672 | $0 | $64,002 | 1.00 | |||
| OLIVIA D POLIUS | |||||||||
| CHIEF FINANCIAL OFFICER | 39.00 | Yes (X) | $348,833 | $0 | $31,967 | 1.00 | |||
| JERRY KUO | |||||||||
| CHIEF OF STRATEGIC FINANCE | 39.00 | Yes (X) | $215,587 | $0 | $55,953 | 1.00 | |||
| BRIAN N NEVILLE | |||||||||
| CHIEF OF ACCOUNTING | 39.00 | Yes (X) | $223,677 | $0 | $34,710 | 1.00 | |||
| PRAVEEN RAJA | |||||||||
| CHIEF OPERATING OFFICER | 39.00 | $408,540 | $0 | $39,837 | 1.00 | Yes (X) | |||
| DAVID C KASLOW | |||||||||
| VP - ESSENTIAL MEDICNES | 39.00 | $383,540 | $0 | $66,181 | 1.00 | Yes (X) | |||
| JEFFREY D BERNSON | |||||||||
| VP - TECH, ANALYTICS, & MRKT INNOV. | 40.00 | $373,374 | $0 | $57,347 | Yes (X) | ||||
| DAVID W FLEMING | |||||||||
| VP - PUBLIC HEALTH | 40.00 | $301,683 | $0 | $48,312 | Yes (X) | ||||
| ELAINE L GIBBONS | |||||||||
| VP - GLOBAL ENGAGEMENT | 40.00 | $250,039 | $0 | $72,215 | Yes (X) | ||||
| MOLLI M BARNES | |||||||||
| CHIEF PEOPLE OFFICER | 40.00 | $216,837 | $0 | $47,872 | Yes (X) | ||||
| ERICA JANE SESSLE | |||||||||
| CHIEF OF STAFF | 40.00 | $214,896 | $0 | $36,881 | Yes (X) | ||||
| SABRINA L POWERS | |||||||||
| GENERAL COUNSEL | 40.00 | $161,635 | $0 | $31,739 | Yes (X) | ||||
| TRAD M HATTON | |||||||||
| COUNTRY DIRECTOR | 40.00 | $333,412 | $0 | $49,783 | Yes (X) | ||||
| JAMES B MCKENNA | |||||||||
| DEPUTY DIRECTOR | 40.00 | $290,281 | $0 | $77,625 | Yes (X) | ||||
| ASHLEY J BIRKETT | |||||||||
| GLOBAL HEAD, MALARIA VACCINES | 40.00 | $310,040 | $0 | $59,402 | Yes (X) | ||||
| BRUCE LAMONT INNIS | |||||||||
| GLOBAL HEAD, RESPIRATORY INFECTIONS | 40.00 | $320,624 | $0 | $32,892 | Yes (X) | ||||
| JOHN O KONZ | |||||||||
| GLOBAL HEAD, FINANCIAL MANAGEMENT | 40.00 | $312,968 | $0 | $61,168 | Yes (X) | ||||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Reportable Comp From Org | $5,226,638 | TotalReportableCompFromOrgAmt |
| Tot Reportable Comp Rltd Org | $0 | TotReportableCompRltdOrgAmt |
| Total Other Compensation | $867,886 | TotalOtherCompensationAmt |
| Indiv Rcvd Greater Than100 K | 318 | IndivRcvdGreaterThan100KCnt |
| Former Ofcr Employees Listed | 0 | FormerOfcrEmployeesListedInd |
| Total Comp Greater Than150 K | Yes (1) | TotalCompGreaterThan150KInd |
| Compensation From Other Srcs | 0 | CompensationFromOtherSrcsInd |
Contractor Compensation ContractorCompensationGrp (5 entries)
| Address Line1ContractorAddress/USAddress/AddressLine1Txt | CityContractorAddress/USAddress/CityNm | State AbbreviationContractorAddress/USAddress/StateAbbreviationCd | ZIPContractorAddress/USAddress/ZIPCd | ServicesServicesDesc | CompensationCompensationAmt | Address Line1ContractorAddress/ForeignAddress/AddressLine1Txt | CityContractorAddress/ForeignAddress/CityNm | CountryContractorAddress/ForeignAddress/CountryCd | Foreign PostalContractorAddress/ForeignAddress/ForeignPostalCd |
|---|---|---|---|---|---|---|---|---|---|
| WMBE PAYROLLING DBA TARGETCW | |||||||||
| 9475 CHESAPEAKE DR | SAN DIEGO | CA | 92123 | GENERAL CONTRACTOR | $726,012 | ||||
| AIRCRUISE TRAVELS PVT LTD | |||||||||
| TRAVEL SERVICES | $522,166 | C 101 - 102 LAJPAT NAGAR 1 | NEW DELHI | IN | 110024 | ||||
| UNIT4 BUSINESS SOFTWARE INC | |||||||||
| 3 BURLINGTON WOODS SUITE 201 | BURLINGTON | MA | 01803 | SYSTEMS CONTRACTOR | $414,490 | ||||
| RANDSTAD INDIA PVT LTD | |||||||||
| STAFFING SERVICES | $391,145 | SUIT NO 001 002 COPIA | NEW DELHI | IN | 110025 | ||||
| CLARK NUBER & CO PS | |||||||||
| 10900 NE 4TH ST SUITE 1400 | BELLEVUE | WA | 98004 | ACCOUNTING SERVICES | $375,309 | ||||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Cntrct Rcvd Greater Than100 K | 46 | CntrctRcvdGreaterThan100KCnt |
| Related Organizations | $4,265,711 | RelatedOrganizationsAmt |
| Government Grants | $106,320,456 | GovernmentGrantsAmt |
| All Other Contributions | $176,222,378 | AllOtherContributionsAmt |
| Noncash Contributions | $4,343,453 | NoncashContributionsAmt |
| Total Contributions | $286,808,545 | TotalContributionsAmt |
Program Service Revenue ProgramServiceRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Desc | CONSULTANCIES | Desc |
| Business | 541900 | BusinessCd |
| Total Revenue Column | $2,038 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $2,038 | RelatedOrExemptFuncIncomeAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Program Service Revenue | $2,038 | TotalProgramServiceRevenueAmt |
Investment Income InvestmentIncomeGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $6,310,221 | TotalRevenueColumnAmt |
| Exclusion | $6,310,221 | ExclusionAmt |
Gross Amount Sales Assets GrossAmountSalesAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $89,753,987 | SecuritiesAmt |
| Other | $38,000 | OtherAmt |
Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $89,190,233 | SecuritiesAmt |
| Other | $188,547 | OtherAmt |
Gain Or Loss GainOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $563,754 | SecuritiesAmt |
| Other | -$150,547 | OtherAmt |
Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $413,207 | TotalRevenueColumnAmt |
| Exclusion | $413,207 | ExclusionAmt |
Other Revenue Misc OtherRevenueMiscGrp (2 entries)
| DescDesc | BusinessBusinessCd | Total Revenue ColumnTotalRevenueColumnAmt | ExclusionExclusionAmt |
|---|---|---|---|
| OTHER | 900099 | $806,343 | $806,343 |
| REIMBURSEMENTS | 900099 | $30,527 | $30,527 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Revenue Total | $836,870 | OtherRevenueTotalAmt |
Total Revenue TotalRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $294,370,881 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $2,038 | RelatedOrExemptFuncIncomeAmt |
| Unrelated Business Revenue | $0 | UnrelatedBusinessRevenueAmt |
| Exclusion | $7,560,298 | ExclusionAmt |
Grants To Domestic Orgs GrantsToDomesticOrgsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $16,151,505 | TotalAmt |
| Program Services | $16,151,505 | ProgramServicesAmt |
Grants To Domestic Individuals GrantsToDomesticIndividualsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $10,313 | TotalAmt |
| Program Services | $10,313 | ProgramServicesAmt |
Foreign Grants ForeignGrantsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $39,457,262 | TotalAmt |
| Program Services | $39,457,262 | ProgramServicesAmt |
Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $4,246,329 | TotalAmt |
| Program Services | $659,952 | ProgramServicesAmt |
| Management And General | $3,555,676 | ManagementAndGeneralAmt |
| Fundraising | $30,701 | FundraisingAmt |
Other Salaries And Wages OtherSalariesAndWagesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $95,165,062 | TotalAmt |
| Program Services | $85,092,916 | ProgramServicesAmt |
| Management And General | $8,828,907 | ManagementAndGeneralAmt |
| Fundraising | $1,243,239 | FundraisingAmt |
Pension Plan Contributions PensionPlanContributionsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $10,334,465 | TotalAmt |
| Program Services | $8,600,526 | ProgramServicesAmt |
| Management And General | $1,597,257 | ManagementAndGeneralAmt |
| Fundraising | $136,682 | FundraisingAmt |
Other Employee Benefits OtherEmployeeBenefitsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $15,489,969 | TotalAmt |
| Program Services | $13,144,164 | ProgramServicesAmt |
| Management And General | $2,160,891 | ManagementAndGeneralAmt |
| Fundraising | $184,914 | FundraisingAmt |
Payroll Taxes PayrollTaxesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $6,354,673 | TotalAmt |
| Program Services | $5,288,484 | ProgramServicesAmt |
| Management And General | $982,144 | ManagementAndGeneralAmt |
| Fundraising | $84,045 | FundraisingAmt |
Fees For Services Legal FeesForServicesLegalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $551,399 | TotalAmt |
| Program Services | $374,203 | ProgramServicesAmt |
| Management And General | $177,196 | ManagementAndGeneralAmt |
Fees For Services Accounting FeesForServicesAccountingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $483,910 | TotalAmt |
| Program Services | $91,666 | ProgramServicesAmt |
| Management And General | $392,244 | ManagementAndGeneralAmt |
Fees For Services Lobbying FeesForServicesLobbyingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,986 | TotalAmt |
| Program Services | $2,986 | ProgramServicesAmt |
Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $186,964 | TotalAmt |
| Management And General | $186,964 | ManagementAndGeneralAmt |
Fees For Services Other FeesForServicesOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $15,623,175 | TotalAmt |
| Program Services | $11,637,627 | ProgramServicesAmt |
| Management And General | $3,756,218 | ManagementAndGeneralAmt |
| Fundraising | $229,330 | FundraisingAmt |
Advertising AdvertisingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $198,936 | TotalAmt |
| Program Services | $179,102 | ProgramServicesAmt |
| Management And General | $5,043 | ManagementAndGeneralAmt |
| Fundraising | $14,791 | FundraisingAmt |
Office Expenses OfficeExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $6,900,163 | TotalAmt |
| Program Services | $5,434,596 | ProgramServicesAmt |
| Management And General | $1,382,874 | ManagementAndGeneralAmt |
| Fundraising | $82,693 | FundraisingAmt |
Information Technology InformationTechnologyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,363,777 | TotalAmt |
| Program Services | $450,053 | ProgramServicesAmt |
| Management And General | $899,342 | ManagementAndGeneralAmt |
| Fundraising | $14,382 | FundraisingAmt |
Royalties RoyaltiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $46,984 | TotalAmt |
| Program Services | $46,984 | ProgramServicesAmt |
Occupancy OccupancyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $12,090,090 | TotalAmt |
| Program Services | $228,951 | ProgramServicesAmt |
| Management And General | $11,861,139 | ManagementAndGeneralAmt |
Travel TravelGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $18,810,123 | TotalAmt |
| Program Services | $17,257,403 | ProgramServicesAmt |
| Management And General | $1,525,961 | ManagementAndGeneralAmt |
| Fundraising | $26,759 | FundraisingAmt |
Conferences Meetings ConferencesMeetingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $8,225,745 | TotalAmt |
| Program Services | $8,102,741 | ProgramServicesAmt |
| Management And General | $66,093 | ManagementAndGeneralAmt |
| Fundraising | $56,911 | FundraisingAmt |
Interest InterestGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,901 | TotalAmt |
| Program Services | $2 | ProgramServicesAmt |
| Management And General | $1,899 | ManagementAndGeneralAmt |
Depreciation Depletion DepreciationDepletionGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $3,202,950 | TotalAmt |
| Program Services | $12,403 | ProgramServicesAmt |
| Management And General | $3,190,547 | ManagementAndGeneralAmt |
Insurance InsuranceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $669,187 | TotalAmt |
| Program Services | $212,403 | ProgramServicesAmt |
| Management And General | $456,784 | ManagementAndGeneralAmt |
Other Expenses OtherExpensesGrp (4 entries)
| DescDesc | TotalTotalAmt | Program ServicesProgramServicesAmt | Management And GeneralManagementAndGeneralAmt | FundraisingFundraisingAmt |
|---|---|---|---|---|
| SUBCONTRACTORS | $25,505,228 | $25,366,038 | $139,190 | |
| EQUIP RENT & MAINT | $3,622,319 | $2,157,809 | $1,461,681 | $2,829 |
| DIRECT AID TO BENEFICIA | $3,034,623 | $3,034,623 | ||
| FACILITIES ALLOC | $0 | $13,042,418 | -$13,264,007 | $221,589 |
All Other Expenses AllOtherExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $4,578,801 | TotalAmt |
| Program Services | $1,675,877 | ProgramServicesAmt |
| Management And General | $2,552,439 | ManagementAndGeneralAmt |
| Fundraising | $350,485 | FundraisingAmt |
Total Functional Expenses TotalFunctionalExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $292,308,839 | TotalAmt |
| Program Services | $257,713,007 | ProgramServicesAmt |
| Management And General | $31,916,482 | ManagementAndGeneralAmt |
| Fundraising | $2,679,350 | FundraisingAmt |
Cash Non Interest Bearing CashNonInterestBearingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $7,576,050 | BOYAmt |
| EOY | $8,845,877 | EOYAmt |
Savings And Temp Cash Invst SavingsAndTempCashInvstGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $14,017,223 | BOYAmt |
| EOY | $17,517,988 | EOYAmt |
Pledges And Grants Receivable PledgesAndGrantsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $35,571,476 | BOYAmt |
| EOY | $44,215,907 | EOYAmt |
Accounts Receivable AccountsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $10,652,789 | BOYAmt |
| EOY | $16,731,594 | EOYAmt |
Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $5,307,245 | BOYAmt |
| EOY | $7,170,218 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Land Bldg Equip Cost Or Other Bss | $36,971,911 | LandBldgEquipCostOrOtherBssAmt |
| Land Bldg Equip Accum Deprec | $26,980,281 | LandBldgEquipAccumDeprecAmt |
Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $11,047,905 | BOYAmt |
| EOY | $9,991,630 | EOYAmt |
Investments Pub Traded Sec InvestmentsPubTradedSecGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $153,328,545 | BOYAmt |
| EOY | $138,590,941 | EOYAmt |
Total Assets TotalAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $237,501,233 | BOYAmt |
| EOY | $243,064,155 | EOYAmt |
Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $202,736,996 | BOYAmt |
| EOY | $204,045,574 | EOYAmt |
Mortg Notes Pybl Scrd Invst Prop MortgNotesPyblScrdInvstPropGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $194,878 | BOYAmt |
Total Liabilities TotalLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $202,931,874 | BOYAmt |
| EOY | $204,045,574 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Organization Follows FASB117 | Yes (X) | OrganizationFollowsFASB117Ind |
No Donor Restriction Net Assets NoDonorRestrictionNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $19,811,400 | BOYAmt |
| EOY | $20,518,990 | EOYAmt |
Donor Restriction Net Assets DonorRestrictionNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $14,757,959 | BOYAmt |
| EOY | $18,499,591 | EOYAmt |
Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $34,569,359 | BOYAmt |
| EOY | $39,018,581 | EOYAmt |
Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $237,501,233 | BOYAmt |
| EOY | $243,064,155 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Reconcilation Revenue Expnss | $2,062,042 | ReconcilationRevenueExpnssAmt |
| Net Unrlzd Gains Losses Invst | $2,387,180 | NetUnrlzdGainsLossesInvstAmt |
| Other Changes In Net Assets | $0 | OtherChangesInNetAssetsAmt |
| Method Of Accounting Accrual | Yes (X) | MethodOfAccountingAccrualInd |
| Accountant Compile Or Review | 0 | AccountantCompileOrReviewInd |
| FS Audited | Yes (1) | FSAuditedInd |
FS Audited Basis FSAuditedBasisGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Consolidated Basis Fincl Stmt | Yes (X) | ConsolidatedBasisFinclStmtInd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Audit Committee | Yes (1) | AuditCommitteeInd |
| Federal Grant Audit Required | Yes (1) | FederalGrantAuditRequiredInd |
| Federal Grant Audit Performed | Yes (1) | FederalGrantAuditPerformedInd |
Schedule A IRS990ScheduleA
| Field | Value | IRS element (for citing) |
|---|---|---|
| Public Organization170 | Yes (X) | PublicOrganization170Ind |
Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $243,499,792 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $298,315,988 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $347,844,394 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $305,316,107 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $286,808,545 | CurrentTaxYearAmt |
| Total | $1,481,784,826 | TotalAmt |
Total Calendar Year170 TotalCalendarYear170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $243,499,792 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $298,315,988 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $347,844,394 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $305,316,107 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $286,808,545 | CurrentTaxYearAmt |
| Total | $1,481,784,826 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Substantial Contributors Tot | $635,757,173 | SubstantialContributorsTotAmt |
| Public Support Total170 | $846,027,653 | PublicSupportTotal170Amt |
Gross Investment Income170 GrossInvestmentIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $1,471,233 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $1,797,794 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $2,050,888 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $2,963,587 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $6,310,221 | CurrentTaxYearAmt |
| Total | $14,593,723 | TotalAmt |
Other Income170 OtherIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $2,551,502 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $4,668,393 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $5,225,302 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $980,560 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $836,870 | CurrentTaxYearAmt |
| Total | $14,262,627 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Support | $1,510,641,176 | TotalSupportAmt |
| Gross Receipts Rltd Activities | $230,357 | GrossReceiptsRltdActivitiesAmt |
| Public Support CY170 | 0.56000 | PublicSupportCY170Pct |
| Public Support PY170 | 0.55410 | PublicSupportPY170Pct |
| Thirty Thr Pct Suprt Tests CY170 | Yes (X) | ThirtyThrPctSuprtTestsCY170Ind |
Schedule B IRS990ScheduleB
Contributor Information ContributorInformationGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Contributor | RESTRICTED | ContributorNum |
Contributor Business Name ContributorBusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | RESTRICTED | BusinessNameLine1 |
Contributor US Address ContributorUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | RESTRICTED | AddressLine1 |
| Address Line2 | RESTRICTED | AddressLine2 |
| City | RESTRICTED | City |
| State | RESTRICTED | State |
| ZIP Code | RESTRICTED | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Contributions | RESTRICTED | TotalContributionsAmt |
Schedule C IRS990ScheduleC
Total Direct Lobbying TotalDirectLobbyingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $163,912 | FilingOrganizationsTotalAmt |
Total Lobbying Expend TotalLobbyingExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $163,912 | FilingOrganizationsTotalAmt |
Other Exempt Purpose Expend OtherExemptPurposeExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $292,144,927 | FilingOrganizationsTotalAmt |
Total Exempt Purpose Expend TotalExemptPurposeExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $292,308,839 | FilingOrganizationsTotalAmt |
Lobbying Nontaxable Amount LobbyingNontaxableAmountGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $1,000,000 | FilingOrganizationsTotalAmt |
Grassroots Nontaxable GrassrootsNontaxableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $250,000 | FilingOrganizationsTotalAmt |
Tot Lbbyng Grassroot Mns Non Tx TotLbbyngGrassrootMnsNonTxGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $0 | FilingOrganizationsTotalAmt |
Tot Lbby Expend Mns Lbbyng Non Tx TotLbbyExpendMnsLbbyngNonTxGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $0 | FilingOrganizationsTotalAmt |
Avg Lobbying Nontaxable Amount AvgLobbyingNontaxableAmountGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Year Minus3 | $1,000,000 | CurrentYearMinus3Amt |
| Current Year Minus2 | $1,000,000 | CurrentYearMinus2Amt |
| Current Year Minus1 | $1,000,000 | CurrentYearMinus1Amt |
| Current Year | $1,000,000 | CurrentYearAmt |
| Total | $4,000,000 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Lobbying Ceiling | $6,000,000 | LobbyingCeilingAmt |
Avg Total Lobbying Expend AvgTotalLobbyingExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Year Minus3 | $168,991 | CurrentYearMinus3Amt |
| Current Year Minus2 | $294,096 | CurrentYearMinus2Amt |
| Current Year Minus1 | $224,944 | CurrentYearMinus1Amt |
| Current Year | $163,912 | CurrentYearAmt |
| Total | $851,943 | TotalAmt |
Avg Grassroots Nontaxable AvgGrassrootsNontaxableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Year Minus3 | $250,000 | CurrentYearMinus3Amt |
| Current Year Minus2 | $250,000 | CurrentYearMinus2Amt |
| Current Year Minus1 | $250,000 | CurrentYearMinus1Amt |
| Current Year | $250,000 | CurrentYearAmt |
| Total | $1,000,000 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grassroots Ceiling | $1,500,000 | GrassrootsCeilingAmt |
Avg Grassroots Lobbying Expend AvgGrassrootsLobbyingExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Year Minus3 | $470 | CurrentYearMinus3Amt |
| Current Year Minus2 | $127,336 | CurrentYearMinus2Amt |
| Current Year Minus1 | $7,856 | CurrentYearMinus1Amt |
| Total | $135,662 | TotalAmt |
Schedule D IRS990ScheduleD
CY Endwmt Fund CYEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $9,095,917 | BeginningYearBalanceAmt |
| Contributions | $2,100 | ContributionsAmt |
| Investment Earnings Or Losses | $1,691,617 | InvestmentEarningsOrLossesAmt |
| Other Expenditures | $502,521 | OtherExpendituresAmt |
| End Year Balance | $10,287,113 | EndYearBalanceAmt |
CY Minus1 Yr Endwmt Fund CYMinus1YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $10,056,545 | BeginningYearBalanceAmt |
| Contributions | $1,240 | ContributionsAmt |
| Investment Earnings Or Losses | -$494,491 | InvestmentEarningsOrLossesAmt |
| Other Expenditures | $467,377 | OtherExpendituresAmt |
| End Year Balance | $9,095,917 | EndYearBalanceAmt |
CY Minus2 Yr Endwmt Fund CYMinus2YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $9,339,249 | BeginningYearBalanceAmt |
| Contributions | $3,410 | ContributionsAmt |
| Investment Earnings Or Losses | $1,159,282 | InvestmentEarningsOrLossesAmt |
| Other Expenditures | $445,396 | OtherExpendituresAmt |
| End Year Balance | $10,056,545 | EndYearBalanceAmt |
CY Minus3 Yr Endwmt Fund CYMinus3YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $8,897,224 | BeginningYearBalanceAmt |
| Contributions | $4,256 | ContributionsAmt |
| Investment Earnings Or Losses | $907,978 | InvestmentEarningsOrLossesAmt |
| Other Expenditures | $470,209 | OtherExpendituresAmt |
| End Year Balance | $9,339,249 | EndYearBalanceAmt |
CY Minus4 Yr Endwmt Fund CYMinus4YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $9,404,188 | BeginningYearBalanceAmt |
| Contributions | $2,665 | ContributionsAmt |
| Investment Earnings Or Losses | -$58,783 | InvestmentEarningsOrLossesAmt |
| Other Expenditures | $450,846 | OtherExpendituresAmt |
| End Year Balance | $8,897,224 | EndYearBalanceAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Board Designated Balance EOY | 0.36000 | BoardDesignatedBalanceEOYPct |
| Prmnnt Endowment Balance EOY | 0.33000 | PrmnntEndowmentBalanceEOYPct |
| Term Endowment Balance EOY | 0.31000 | TermEndowmentBalanceEOYPct |
| Endowments Held Unrelated Org | 0 | EndowmentsHeldUnrelatedOrgInd |
| Endowments Held Related Org | 0 | EndowmentsHeldRelatedOrgInd |
Leasehold Improvements LeaseholdImprovementsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $20,566,785 | OtherCostOrOtherBasisAmt |
| Depreciation | $14,121,217 | DepreciationAmt |
| Book Value | $6,445,568 | BookValueAmt |
Equipment EquipmentGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $10,413,970 | OtherCostOrOtherBasisAmt |
| Depreciation | $6,867,909 | DepreciationAmt |
| Book Value | $3,546,061 | BookValueAmt |
Other Land Buildings OtherLandBuildingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $5,991,156 | OtherCostOrOtherBasisAmt |
| Depreciation | $5,991,155 | DepreciationAmt |
| Book Value | $1 | BookValueAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Book Value Land Buildings | $9,991,630 | TotalBookValueLandBuildingsAmt |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART V, LINE 4: | FormAndLineReferenceDesc |
| Explanation | PATH UTILIZES THE INVESTED INTREST EARNINGS FROM THE ENDOWMENT AS AN IMPORTANT FUNDING SOURCE TO FUND NEW OPPORTUNITIES TO EXPAND ITS REACH AND IMPACT AS AN ORGANIZATION IN THE FIELD OF GLOBAL HEALTH, IN ACCORDANCE WITH PATH'S ENDOWMENT SPENDING POLICY. | ExplanationTxt |
Schedule F IRS990ScheduleF
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (1) | GrantRecordsMaintainedInd |
Account Activities Outside US AccountActivitiesOutsideUSGrp (50 entries)
| RegionRegionTxt | OfficesOfficesCnt | EmployeeEmployeeCnt | Type Of Activities ConductedTypeOfActivitiesConductedTxt | Region Total ExpendituresRegionTotalExpendituresAmt | Specific Services ProvidedSpecificServicesProvidedTxt |
|---|---|---|---|---|---|
| CENTRAL AMERICA AND THE CARIBBEAN | 0 | 0 | MANAGEMENT & GENERAL | $1,337,651 | |
| CENTRAL AMERICA AND THE CARIBBEAN | 0 | 0 | PROGRAM SERVICES | $256,127 | GLOBAL HEALTH PROGRAM |
| CENTRAL AMERICA AND THE CARIBBEAN | 0 | 0 | PROGRAM SERVICES | $77,366 | ESSENTIAL MEDICINE |
| CENTRAL AMERICA AND THE CARIBBEAN | 0 | 0 | PROGRAM SERVICES | $214,517 | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION |
| CENTRAL AMERICA AND THE CARIBBEAN | 0 | 0 | PROGRAM SERVICES | $49,145 | OTHER |
| CENTRAL AMERICA AND THE CARIBBEAN | 0 | 0 | FUNDRAISING | $116,688 | |
| CENTRAL AMERICA AND THE CARIBBEAN | 0 | 0 | GRANTMAKING | $240,108 | |
| EAST ASIA AND THE PACIFIC | 5 | 89 | MANAGEMENT & GENERAL | $1,166,381 | |
| EAST ASIA AND THE PACIFIC | 0 | 0 | PROGRAM SERVICES | $4,770,576 | GLOBAL HEALTH PROGRAM |
| EAST ASIA AND THE PACIFIC | 0 | 0 | PROGRAM SERVICES | $278,686 | ESSENTIAL MEDICINE |
| EAST ASIA AND THE PACIFIC | 0 | 0 | PROGRAM SERVICES | $76,122 | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION |
| EAST ASIA AND THE PACIFIC | 0 | 0 | FUNDRAISING | $35,433 | |
| EAST ASIA AND THE PACIFIC | 0 | 0 | GRANTMAKING | $5,952,808 | |
| EUROPE | 1 | 6 | MANAGEMENT & GENERAL | $117,977 | |
| EUROPE | 0 | 0 | PROGRAM SERVICES | $4,594,053 | GLOBAL HEALTH PROGRAM |
| EUROPE | 0 | 0 | PROGRAM SERVICES | $7,399,289 | ESSENTIAL MEDICINE |
| EUROPE | 0 | 0 | PROGRAM SERVICES | $412,185 | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION |
| EUROPE | 0 | 0 | PROGRAM SERVICES | $118,911 | OTHER |
| EUROPE | 0 | 0 | GRANTMAKING | $17,408,213 | |
| MIDDLE EAST AND NORTH AFRICA | 0 | 0 | MANAGEMENT & GENERAL | $28,381 | |
| MIDDLE EAST AND NORTH AFRICA | 0 | 0 | PROGRAM SERVICES | $2,116 | GLOBAL HEALTH PROGRAM |
| MIDDLE EAST AND NORTH AFRICA | 0 | 0 | PROGRAM SERVICES | $7,000 | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION |
| NORTH AMERICA | 0 | 0 | MANAGEMENT & GENERAL | $75,082 | |
| NORTH AMERICA | 0 | 0 | PROGRAM SERVICES | $115,188 | GLOBAL HEALTH PROGRAM |
| NORTH AMERICA | 0 | 0 | PROGRAM SERVICES | $160,628 | ESSENTIAL MEDICINE |
| NORTH AMERICA | 0 | 0 | PROGRAM SERVICES | $1,975 | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION |
| NORTH AMERICA | 0 | 0 | PROGRAM SERVICES | $6,704 | OTHER |
| NORTH AMERICA | 0 | 0 | FUNDRAISING | $11,176 | |
| NORTH AMERICA | 0 | 0 | GRANTMAKING | $400,353 | |
| RUSSIA AND NEIGHBORING STATES | 1 | 24 | MANAGEMENT & GENERAL | $238,347 | |
| RUSSIA AND NEIGHBORING STATES | 0 | 0 | PROGRAM SERVICES | $2,653,697 | GLOBAL HEALTH PROGRAM |
| RUSSIA AND NEIGHBORING STATES | 0 | 0 | GRANTMAKING | $1,042,939 | |
| SOUTH AMERICA | 1 | 2 | MANAGEMENT & GENERAL | $76,277 | |
| SOUTH AMERICA | 0 | 0 | PROGRAM SERVICES | $275,814 | GLOBAL HEALTH PROGRAM |
| SOUTH AMERICA | 0 | 0 | PROGRAM SERVICES | $3,083 | ESSENTIAL MEDICINE |
| SOUTH AMERICA | 0 | 0 | PROGRAM SERVICES | $27,772 | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION |
| SOUTH AMERICA | 0 | 0 | PROGRAM SERVICES | $1,360 | OTHER |
| SOUTH AMERICA | 0 | 0 | GRANTMAKING | $333,947 | |
| SOUTH ASIA | 6 | 122 | MANAGEMENT & GENERAL | $1,889,812 | |
| SOUTH ASIA | 0 | 0 | PROGRAM SERVICES | $5,241,530 | GLOBAL HEALTH PROGRAM |
| SOUTH ASIA | 0 | 0 | PROGRAM SERVICES | $1,161,152 | ESSENTIAL MEDICINE |
| SOUTH ASIA | 0 | 0 | PROGRAM SERVICES | $601,147 | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION |
| SOUTH ASIA | 0 | 0 | GRANTMAKING | $2,673,505 | |
| SUB-SAHARAN AFRICA | 48 | 728 | MANAGEMENT & GENERAL | $10,720,815 | |
| SUB-SAHARAN AFRICA | 0 | 0 | PROGRAM SERVICES | $45,897,726 | GLOBAL HEALTH PROGRAM |
| SUB-SAHARAN AFRICA | 0 | 0 | PROGRAM SERVICES | $2,174,274 | ESSENTIAL MEDICINE |
| SUB-SAHARAN AFRICA | 0 | 0 | PROGRAM SERVICES | $1,383,395 | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION |
| SUB-SAHARAN AFRICA | 0 | 0 | PROGRAM SERVICES | $2,069,259 | OTHER |
| SUB-SAHARAN AFRICA | 0 | 0 | FUNDRAISING | $3,389 | |
| SUB-SAHARAN AFRICA | 0 | 0 | GRANTMAKING | $11,415,702 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Subtotal Offices | 5 | SubtotalOfficesCnt |
| Subtotal Employees | 89 | SubtotalEmployeesCnt |
| Continuation Total Office | 57 | ContinuationTotalOfficeCnt |
| Continuation Total Employee | 882 | ContinuationTotalEmployeeCnt |
| Total Office | 62 | TotalOfficeCnt |
| Total Employee | 971 | TotalEmployeeCnt |
| Subtotal Spent | $3,457,983 | SubtotalSpentAmt |
| Continuation Spent | $131,857,798 | ContinuationSpentAmt |
| Total Spent | $135,315,781 | TotalSpentAmt |
Grants To Org Outside US GrantsToOrgOutsideUSGrp (167 entries)
| RegionRegionTxt | Purpose Of GrantPurposeOfGrantTxt | Cash GrantCashGrantAmt | Manner Of Cash DisbursementMannerOfCashDisbursementTxt |
|---|---|---|---|
| CENTRAL AMERICA & THE CARIBBEAN | GLOBAL HEALTH PROGRAMS | $93,018 | CHECK/WIRE |
| CENTRAL AMERICA & THE CARIBBEAN | GLOBAL HEALTH PROGRAMS | $147,089 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | GLOBAL HEALTH PROGRAMS | $8,618 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | GLOBAL HEALTH PROGRAMS | $38,912 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | ESSENTIAL MEDICINE | $42,710 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | GLOBAL HEALTH PROGRAMS | $6,425 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | ESSENTIAL MEDICINE | $1,151,570 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | GLOBAL HEALTH PROGRAMS | $33,612 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | GLOBAL HEALTH PROGRAMS | $57,928 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | GLOBAL HEALTH PROGRAMS | $226,137 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | GLOBAL HEALTH PROGRAMS | $23,793 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | ESSENTIAL MEDICINE | $91,336 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | GLOBAL HEALTH PROGRAMS | $39,494 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | GLOBAL HEALTH PROGRAMS | $28,123 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | ESSENTIAL MEDICINE | $25,120 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | ESSENTIAL MEDICINE | $14,241 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | GLOBAL HEALTH PROGRAMS | $17,369 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | $38,380 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | GLOBAL HEALTH PROGRAMS | $86,964 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | ESSENTIAL MEDICINE | $36,332 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | GLOBAL HEALTH PROGRAMS | $124,085 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | ESSENTIAL MEDICINE | $10,222 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | ESSENTIAL MEDICINE & GLOBAL HEALTH PROGRAMS | $330,992 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | GLOBAL HEALTH PROGRAMS | $16,142 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | ESSENTIAL MEDICINE | $2,291,621 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | GLOBAL HEALTH PROGRAMS | $48,002 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | ESSENTIAL MEDICINE | $126,000 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | GLOBAL HEALTH PROGRAMS | $144,834 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | GLOBAL HEALTH PROGRAMS | $7,547 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | $28,627 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | ESSENTIAL MEDICINE | $685,400 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | GLOBAL HEALTH PROGRAMS | $97,367 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | GLOBAL HEALTH PROGRAMS | $50,000 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | GLOBAL HEALTH PROGRAMS | $8,411 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | ESSENTIAL MEDICINE | $16,000 | CHECK/WIRE |
| EUROPE | TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | $198,045 | CHECK/WIRE |
| EUROPE | GLOBAL HEALTH PROGRAMS | $147,352 | CHECK/WIRE |
| EUROPE | GLOBAL HEALTH PROGRAMS | $224,690 | CHECK/WIRE |
| EUROPE | ESSENTIAL MEDICINE | $4,356,625 | CHECK/WIRE |
| EUROPE | GLOBAL HEALTH PROGRAMS | $5,432 | CHECK/WIRE |
| EUROPE | GLOBAL HEALTH PROGRAMS | $44,714 | CHECK/WIRE |
| EUROPE | ESSENTIAL MEDICINE | $184,293 | CHECK/WIRE |
| EUROPE | ESSENTIAL MEDICINE | $276,301 | CHECK/WIRE |
| EUROPE | GLOBAL HEALTH PROGRAMS | $82,353 | CHECK/WIRE |
| EUROPE | GLOBAL HEALTH PROGRAMS | $142,750 | CHECK/WIRE |
| EUROPE | ESSENTIAL MEDICINE | $749,227 | CHECK/WIRE |
| EUROPE | ESSENTIAL MEDICINE | $833,318 | CHECK/WIRE |
| EUROPE | GLOBAL HEALTH PROGRAMS | $46,131 | CHECK/WIRE |
| EUROPE | ESSENTIAL MEDICINE | $412,846 | CHECK/WIRE |
| EUROPE | TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | $488,750 | CHECK/WIRE |
| EUROPE | TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | $123,201 | CHECK/WIRE |
| EUROPE | ESSENTIAL MEDICINE | $43,490 | CHECK/WIRE |
| EUROPE | GLOBAL HEALTH PROGRAMS | $59,982 | CHECK/WIRE |
| EUROPE | TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | $297,425 | CHECK/WIRE |
| EUROPE | ESSENTIAL MEDICINE | $467,701 | CHECK/WIRE |
| EUROPE | ESSENTIAL MEDICINE | $32,000 | CHECK/WIRE |
| EUROPE | GLOBAL HEALTH PROGRAMS | $93,195 | CHECK/WIRE |
| EUROPE | ESSENTIAL MEDICINE | $801,088 | CHECK/WIRE |
| EUROPE | ESSENTIAL MEDICINE | $260,307 | CHECK/WIRE |
| EUROPE | GLOBAL HEALTH PROGRAMS | $26,615 | CHECK/WIRE |
| EUROPE | ESSENTIAL MEDICINE | $225,000 | CHECK/WIRE |
| EUROPE | GLOBAL HEALTH PROGRAMS | $2,176,178 | CHECK/WIRE |
| EUROPE | ESSENTIAL MEDICINE | $236,406 | CHECK/WIRE |
| EUROPE | GLOBAL HEALTH PROGRAMS | $32,721 | CHECK/WIRE |
| EUROPE | GLOBAL HEALTH PROGRAMS AND TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | $270,500 | CHECK/WIRE |
| EUROPE | ESSENTIAL MEDICINE, GLOBAL HEALTH PROGRAMS, TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS, AND OTHER | $4,069,578 | CHECK/WIRE |
| NORTH AMERICA | ESSENTIAL MEDICINE | $81,238 | CHECK/WIRE |
| NORTH AMERICA | ESSENTIAL MEDICINE | $285,226 | CHECK/WIRE |
| NORTH AMERICA | ESSENTIAL MEDICINE | $33,889 | CHECK/WIRE |
| RUSSIA & NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $5,395 | CHECK/WIRE |
| RUSSIA & NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $10,480 | CHECK/WIRE |
| RUSSIA & NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $6,999 | CHECK/WIRE |
| RUSSIA & NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $38,615 | CHECK/WIRE |
| RUSSIA & NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $9,724 | CHECK/WIRE |
| RUSSIA & NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $367,763 | CHECK/WIRE |
| RUSSIA & NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $16,506 | CHECK/WIRE |
| RUSSIA & NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $62,480 | CHECK/WIRE |
| RUSSIA & NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $57,489 | CHECK/WIRE |
| RUSSIA & NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $34,092 | CHECK/WIRE |
| RUSSIA & NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $13,915 | CHECK/WIRE |
| RUSSIA & NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $15,472 | CHECK/WIRE |
| RUSSIA & NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $6,241 | CHECK/WIRE |
| RUSSIA & NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $32,000 | CHECK/WIRE |
| RUSSIA & NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $149,600 | CHECK/WIRE |
| RUSSIA & NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $56,952 | CHECK/WIRE |
| RUSSIA & NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $53,665 | CHECK/WIRE |
| RUSSIA & NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $96,640 | CHECK/WIRE |
| SOUTH AMERICA | GLOBAL HEALTH PROGRAMS | $98,107 | CHECK/WIRE |
| SOUTH AMERICA | GLOBAL HEALTH PROGRAMS | $7,000 | CHECK/WIRE |
| SOUTH AMERICA | GLOBAL HEALTH PROGRAMS | $14,000 | CHECK/WIRE |
| SOUTH AMERICA | GLOBAL HEALTH PROGRAMS | $19,038 | CHECK/WIRE |
| SOUTH AMERICA | TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | $115,115 | CHECK/WIRE |
| SOUTH AMERICA | GLOBAL HEALTH PROGRAMS | $80,687 | CHECK/WIRE |
| SOUTH ASIA | GLOBAL HEALTH PROGRAMS | $10,659 | CHECK/WIRE |
| SOUTH ASIA | GLOBAL HEALTH PROGRAMS AND TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | $67,201 | CHECK/WIRE |
| SOUTH ASIA | GLOBAL HEALTH PROGRAMS | $73,580 | CHECK/WIRE |
| SOUTH ASIA | GLOBAL HEALTH PROGRAMS | $13,650 | CHECK/WIRE |
| SOUTH ASIA | GLOBAL HEALTH PROGRAMS | $49,523 | CHECK/WIRE |
| SOUTH ASIA | TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | $29,364 | CHECK/WIRE |
| SOUTH ASIA | ESSENTIAL MEDICINE & GLOBAL HEALTH PROGRAMS | $82,005 | CHECK/WIRE |
| SOUTH ASIA | GLOBAL HEALTH PROGRAMS | $242,361 | CHECK/WIRE |
| SOUTH ASIA | GLOBAL HEALTH PROGRAMS | $14,893 | CHECK/WIRE |
| SOUTH ASIA | ESSENTIAL MEDICINE | $231,749 | CHECK/WIRE |
| SOUTH ASIA | GLOBAL HEALTH PROGRAMS | $11,391 | CHECK/WIRE |
| SOUTH ASIA | ESSENTIAL MEDICINE | $1,730,177 | CHECK/WIRE |
| SOUTH ASIA | GLOBAL HEALTH PROGRAMS | $19,090 | CHECK/WIRE |
| SOUTH ASIA | ESSENTIAL MEDICINE | $96,782 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $30,892 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $10,396 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $192,598 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $23,691 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $99,655 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $8,927 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | ESSENTIAL MEDICINE | $1,432,181 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $70,504 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $41,751 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $18,034 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | ESSENTIAL MEDICINE | $2,034,653 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | ESSENTIAL MEDICINE | $257,028 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $387,808 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | $57,101 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $29,457 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $7,376 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $50,404 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $12,553 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $28,010 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | OTHER | $126,000 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $38,507 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $149,500 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $379,662 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | $44,465 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $23,267 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS & OTHER | $95,460 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | ESSENTIAL MEDICINE | $272,190 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $1,172,007 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | $67,200 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $12,209 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $74,257 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS & OTHER | $69,137 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | $45,948 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $24,312 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | OTHER | $10,077 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $17,753 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $7,248 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $19,057 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $17,678 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | ESSENTIAL MEDICINE | $378,060 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $48,221 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $14,281 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $87,115 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | $30,755 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | $376,205 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $18,278 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | ESSENTIAL MEDICINE | $25,000 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $5,380 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $698,318 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $17,912 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $13,305 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $534,664 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $184,587 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $268,453 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $23,391 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $1,088,928 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | ESSENTIAL MEDICINE | $25,207 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $57,468 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $18,179 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $24,960 | CHECK/WIRE |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 128 | Total501c3OrgCnt |
| Total Other Org | 39 | TotalOtherOrgCnt |
| Transfer To Foreign Corp | Yes (1) | TransferToForeignCorpInd |
| Interest In Foreign Trust | 0 | InterestInForeignTrustInd |
| Foreign Corp Ownership | 0 | ForeignCorpOwnershipInd |
| Passive Foreign Investmest Co | 0 | PassiveForeignInvestmestCoInd |
| Foreign Partnership | 0 | ForeignPartnershipInd |
| Boycott Countries | 0 | BoycottCountriesInd |
Supplemental Information Detail SupplementalInformationDetail (2 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| PART I, LINE 2: | PATH HAS A SUBRECIPIENT POLICY AND PROCEDURES IN PLACE TO GUIDE THE WAY OUR PROJECT TEAMS MONITOR SUBRECIPIENTS. THIS INCLUDES BOTH FINANCIAL AND TECHNICAL MONITORING. PATH USES RISK ASSESSMENTS, REPORTING, SITE VISITS, REGULAR CONTACT, AND OTHER MEANS TO PROVIDE THE MONITORING REQUIRED BY FUNDERS AND TO ENSURE GOOD PROJECT STEWARDSHIP. THESE ACTIVITIES ALSO PROVIDE RESPONSIBLE ASSURANCE THAT THE SUBRECIPIENT ADMINISTERS FUNDS IN COMPLIANCE WITH LAWS, REGULATIONS, AND PRIME AWARD TERMS AND ACHIEVES PERFORMANCE GOALS. PATH HAS ESTABLISHED COMPREHENSIVE POLICIES AND PROCEDURES TO PROMOTE BEST BUSINESS PRACTICES AND ENSURE EFFICIENT AND EFFECTIVE INTERNAL CONTROL. THESE ARE COMBINED WITH AN INTERNAL AUDIT FUNCTION THROUGH WHICH PATH CONDUCTS AUDITS ON GRANT-FUNDED PROGRAMS TO ENSURE COMPLIANCE WITH REGULATORY REQUIREMENTS. |
| PART III ACCOUNTING METHOD: |
Schedule I IRS990ScheduleI
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (1) | GrantRecordsMaintainedInd |
Recipient Table RecipientTable (64 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | Recipient EINRecipientEIN | IRC SectionIRCSectionDesc | Non Cash AssistanceNonCashAssistanceAmt | Purpose Of GrantPurposeOfGrantTxt | Address Line2USAddress/AddressLine2Txt |
|---|---|---|---|---|---|---|---|---|
| ADARA DEVELOPMENT (USA) | ||||||||
| 300 ADMIRAL WAY SUITE 106 | EDMONDS | WA | 98020 | 980634789 | 501(C)(3) | $11,392 | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION | |
| AJINOMOTO ALTHEA INC (DBA AJINOMOTO BIO-PHARMA SERVICES) | ||||||||
| 11040 ROSELLE STREET | SAN DIEGO | CA | 92121 | 330788907 | 501(C)(3) | $20,340 | ESSENTIAL MEDICINE | |
| APIJECT SYSTEMS CORP | ||||||||
| 2 HIGH RIDGE PARK | STAMFORD | CT | 06905 | 832211917 | 501(C)(3) | $538,000 | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION | |
| BAO SYSTEMS LLC | ||||||||
| 2900 K STREET SUITE 507 | WASHINGTON | DC | 20007 | 272316349 | 501(C)(3) | $94,009 | GLOBAL HEALTH PROGRAMS | |
| BECTON DICKINSON & COMPANY | ||||||||
| ONE BECTON DRIVE | FRANKLIN LAKES | NJ | 07417 | 220760120 | OTHER | $360,513 | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION | |
| BEHAVIORAL IDEAS LAB INC (DBA IDEAS42) | ||||||||
| 80 BROAD STREET 30TH FLOOR | NEW YORK | NY | 10004 | 271678009 | 501(C)(3) | $25,000 | GLOBAL HEALTH PROGRAMS | |
| BENEVOLENT HEALTHCARE FOUNDATION DBA PROJECT CURE | ||||||||
| 10377 E GEDDES AVENUE SUITE 200 | CENTENNIAL | CO | 80112 | 841568566 | 501(C)(3) | $92,495 | GLOBAL HEALTH PROGRAMS | |
| BIOIVT LLC | ||||||||
| 123 FROST STREET STE 115 | WESTBURY | NY | 11590 | 271867431 | OTHER | $77,775 | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION | |
| CARDNO EMERGING MARKETS | ||||||||
| 2107 WILSON BLVD STE 800 | ARLINGTON | VA | 22201 | 521788060 | OTHER | $47,831 | GLOBAL HEALTH PROGRAMS | |
| CASCADE DESIGNS INC | ||||||||
| 4000 1ST AVE SOUTH | SEATTLE | WA | 98134 | 910969695 | OTHER | $26,209 | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION | |
| CENTERS FOR DISEASE CONTROL AND PREVENTION ( CDC ) | ||||||||
| 1600 CLIFTON ROAD | ATLANTA | GA | 30333 | 586051157 | GOV | $142,650 | ESSENTIAL MEDICINE | |
| CHILDREN'S HOSPITAL BOSTON | ||||||||
| RESEARCH FINANCE PO BOX 414413 | BOSTON | MA | 022414413 | 042774441 | 501(C)(3) | $118,856 | ESSENTIAL MEDICINE | |
| CINCINNATI CHILDREN'S HOSPITAL | ||||||||
| MEDICAL CENTER 3333 BURNET AVE ML | CINCINNATI | OH | 452293039 | 310833936 | 501(C)(3) | $90,987 | ESSENTIAL MEDICINE | 6014 |
| DIMAGI INC | ||||||||
| 585 MASSACHUSETTS AVE SUITE 4 | CAMBRIDGE | MA | 02139 | 830343298 | 501(C)(3) | $21,794 | GLOBAL HEALTH PROGRAMS | |
| DUKE UNIVERSITY | ||||||||
| BOX 104132 | DURHAM | NC | 27708 | 560532129 | 501(C)(3) | $61,225 | ESSENTIAL MEDICINE | |
| FINA BIOSOLUTIONS LLC | ||||||||
| 9430 KEY WEST AVE SUITE 200 | ROCKVILLE | MD | 20850 | 205448275 | OTHER | $83,000 | ESSENTIAL MEDICINE | |
| FOOD AND DRUG ADMINISTRATION | ||||||||
| 5600 FISHERS LANEHFA-140 ROOM 11-40 | ROCKVILLE | MD | 20857 | 530196965 | GOV | $50,000 | ESSENTIAL MEDICINE | 11-40 |
| FRED HUTCHINSON CANCER RESEARCH CENTER | ||||||||
| 1100 FAIRVIEW AVE N PO BOX 19024 | SEATTLE | WA | 981091024 | 237156071 | 501(C)(3) | $142,705 | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION | |
| GHP SOLUTIONS LLC | ||||||||
| 220 EAST 42ND STREET SUITE 710 | NEW YORK | NY | 10017 | 061652595 | OTHER | $204,243 | GLOBAL HEALTH PROGRAMS | |
| GLOBAL HEALTH CORPS | ||||||||
| 318 WEST 39TH STREET ROOM 9L | NEW YORK | NY | 10018 | 800512336 | 501(C)(3) | $5,564 | GLOBAL HEALTH PROGRAMS | |
| GLOBAL HEALTH STRATEGIES LLC | ||||||||
| 27 WEST 24TH STREET SUITE 900 | NEW YORK | NY | 10010 | 272494697 | 501(C)(3) | $292,818 | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION | |
| HARVARD SCHOOL OF PUBLIC HEALTH | ||||||||
| 677 HUNTINGTON AVENUE | BOSTON | MA | 02215 | 042103580 | 501(C)(3) | $1,015,118 | ESSENTIAL MEDICINE | |
| HARVARD UNIVERSITY | ||||||||
| 1033 MASSACHUSETTS AVE 2ND FLOOR | CAMBRIDGE | MA | 02115 | 042103580 | 501(C)(3) | $45,101 | ESSENTIAL MEDICINE | |
| HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE INC | ||||||||
| 6720-A ROCKLEDGE DRIVE STE 100 | BETHESDA | MD | 20817 | 521317896 | 501(C)(3) | $30,841 | ESSENTIAL MEDICINE | |
| ICF MACRO INC | ||||||||
| 9300 LEE HIGHWAY | FAIRFAX | VA | 22031 | 223661438 | 501(C)(3) | $1,433,641 | GLOBAL HEALTH PROGRAMS | |
| INITIATIVES INC | ||||||||
| 264 BEACON STREET | BOSTON | MA | 02116 | 042961350 | OTHER | $30,481 | GLOBAL HEALTH PROGRAMS | |
| INTRAHEALTH INTERNATIONAL INC | ||||||||
| 6340 QUADRANGLE DRIVE SUITE 200 | CHAPEL HILL | NC | 27517 | 550825466 | 501(C)(3) | $370,237 | GLOBAL HEALTH PROGRAMS | |
| INVENTPRISE LLC | ||||||||
| 18133 NE 68TH STREET SUITE D 150 | REDMOND | WA | 98052 | 454927373 | OTHER | $229,593 | ESSENTIAL MEDICINE | |
| JHPIEGO | ||||||||
| 1615 THAMES STREET SUITE 200 | BALTIMORE | MD | 212313447 | 237424444 | 501(C)(3) | $14,823 | GLOBAL HEALTH PROGRAMS | |
| JOHNS HOPKINS UNIVERSITY | ||||||||
| BLOOMBERG SCHL OF PUB HLTH 615 N | BALTIMORE | MD | 21205 | 520595110 | 501(C)(3) | $813,659 | ESSENTIAL MEDICINE & GLOBAL HEALTH PROGRAMS | WOLFE STREET |
| JSI RESEARCH AND TRAINING INSTITUTE INC | ||||||||
| 1616 NORTH FORT MYER DR 16TH FLOOR | ARLINGTON | VA | 222093100 | 042679824 | OTHER | $1,187,106 | GLOBAL HEALTH PROGRAMS | |
| KYBELE INC | ||||||||
| 3524 YADKINVILLE ROAD 124 | WINSTONSALEM | NC | 27106 | 900759003 | 501(C)(3) | $91,391 | GLOBAL HEALTH PROGRAMS | |
| LINKSBRIDGE SPC | ||||||||
| 101 TAYLOR AVE N 105 | SEATTLE | WA | 98109 | 263067893 | OTHER | $43,873 | ESSENTIAL MEDICINE | |
| MANAGEMENT SCIENCES FOR HEALTH | ||||||||
| 200 RIVERS EDGE DRIVE SUITE 320 | MEDFORD | MA | 02155 | 042482188 | 501(C)(3) | $63,998 | GLOBAL HEALTH PROGRAMS | |
| MASSACHUSETTS GENERAL HOSPITAL | ||||||||
| DEPT OF EMERGENCY MEDICINE | BOSTON | MA | 02139 | 041564655 | 501(C)(3) | $50,000 | ESSENTIAL MEDICINE | |
| MASSACHUSETTS INSTITUTE OF TECHNOLOGY ( MIT ) | ||||||||
| 77 MASSACHUSETTS AVENUE | CAMBRIDGE | MA | 02139 | 042103594 | 501(C)(3) | $70,000 | ESSENTIAL MEDICINE | |
| MASSBIOLOGICS INC | ||||||||
| 460 WALK HILL STREET | BOSTON | MA | 02126 | 043167352 | 501(C)(3) | $7,250 | ESSENTIAL MEDICINE | |
| NAT'L INST OF ALLERGY & INFECTIOUS DISEASES ( NIAID ) | ||||||||
| 6610 ROCKLEDGE DR ROOM 2800 | BETHESDA | MD | 208926606 | 520858115 | GOV | $824,068 | ESSENTIAL MEDICINE | |
| NICHOLAS INSTITUTE FOR ENVIRONMENTAL POLICY SOLUTIONS AT DUKE UNIVERSITY | ||||||||
| 2117 CAMPUS DRIVE | DURHAM | NC | 27708 | 560532129 | 501(C)(3) | $46,666 | GLOBAL HEALTH PROGRAMS | |
| NYAYA HEALTH (DBA POSSIBLE HEALTH) | ||||||||
| 30 BROAD STREET FLOOR 9 | NEW YORK | NY | 10004 | 203055055 | 501(C)(3) | $81,185 | GLOBAL HEALTH PROGRAMS | |
| ONA SYSTEMS INC | ||||||||
| 126 E 12TH ST SUITE 4A | NEW YORK | NY | 100035320 | 383940780 | OTHER | $116,731 | GLOBAL HEALTH PROGRAMS | |
| OPENMRS INC | ||||||||
| 10425 COMMERCE DR STE 110 | CARMEL | IN | 460327643 | 455316647 | 501(C)(3) | $94,054 | GLOBAL HEALTH PROGRAMS | |
| PANORAMA GLOBAL | ||||||||
| 2101 FOURTH AVENUE STE 2100 | SEATTLE | WA | 98121 | 814204119 | 501(C)(3) | $10,000 | GLOBAL HEALTH PROGRAMS | |
| PATHFINDER INTERNATIONAL | ||||||||
| 9 GALEN STREET SUITE 217 | WATERTOWN | MA | 02472 | 530235320 | 501(C)(3) | $100,867 | GLOBAL HEALTH PROGRAMS | |
| PHARMARON CPC INC | ||||||||
| 800 W BALTIMORE STREET 5TH FLOOR | BALTIMORE | MD | 21201 | 208419781 | 501(C)(3) | $687,836 | ESSENTIAL MEDICINE | |
| POPULATION COUNCIL | ||||||||
| ONE DAG HAMMARSKJOLD PLAZA | NEW YORK | NY | 10017 | 131687001 | 501(C)(3) | $146,121 | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION | |
| POPULATION SERVICES INTERNATIONAL INC | ||||||||
| 1120 19TH ST NW STE 600 | WASHINGTON | DC | 20036 | 560942853 | 501(C)(3) | $63,300 | GLOBAL HEALTH PROGRAMS | |
| ROSTROPOVICH-VISHNEVSKAYA FOUNDATION | ||||||||
| 1776 K STREET NW SUITE 700 | WASHINGTON | DC | 20006 | 521752473 | 501(C)(3) | $152,378 | ESSENTIAL MEDICINE | |
| SOLAR ELECTRIC LIGHT FUND | ||||||||
| 1612 K STREET NW SUITE 300 | WASHINGTON | DC | 20006 | 521701564 | 501(C)(3) | $46,778 | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION | |
| TECHCHANGE INC | ||||||||
| 2001 13TH ST NW 2ND FLOOR | WASHINGTON | DC | 20009 | 273358772 | OTHER | $64,664 | GLOBAL HEALTH PROGRAMS | |
| THE NATURE CONSERVANCY | ||||||||
| 4245 FAIRFAX DRIVE | ARLINGTON | VA | 22203 | 530242652 | 501(C)(3) | $9,500 | GLOBAL HEALTH PROGRAMS | |
| THE SCRIPPS RESEARCH INSTITUTE ( TSRI ) | ||||||||
| 10550 N TORREY PINES ROAD | LA JOLLA | CA | 92037 | 330435954 | 501(C)(3) | $131,834 | ESSENTIAL MEDICINE | |
| THE STATE UNIVERSITY OF NEW YORK | ||||||||
| 35 STATE STREET | ALBANY | NY | 122072826 | 146013200 | 501(C)(3) | $143,437 | ESSENTIAL MEDICINE | |
| THE UNIVERSITY OF TEXAS AT AUSTIN | ||||||||
| 110 INNER CAMPUS DRIVE STOP K5300 | AUSTIN | TX | 78712 | 746000203 | GOV | $82,294 | ESSENTIAL MEDICINE | |
| THE WILLIAM DAVIDSON INST AT THE UNIV OF MICHIGAN ( WDI ) | ||||||||
| 724 E UNIVERSITY AVE WYLY HALL | ANN ARBOR | MI | 48109 | 383048086 | 501(C)(3) | $20,178 | GLOBAL HEALTH PROGRAMS | FIRST FLOOR |
| TULANE UNIVERSITY | ||||||||
| 6823 ST CHARLES AVE | NEW ORLEANS | LA | 70112 | 720423889 | 501(C)(3) | $372,590 | GLOBAL HEALTH PROGRAMS | |
| UNIVERSITY OF MARYLAND BALTIMORE | ||||||||
| PO BOX 41428 | BALTIMORE | MD | 21203 | 526002033 | 501(C)(3) | $87,010 | ESSENTIAL MEDICINE | |
| UNIVERSITY OF MASSACHUSETTS | ||||||||
| MEDICAL SCHOOL 55 LAKE AVENUE NORTH | WORCESTER | MA | 01655 | 043167352 | GOV | $137,500 | ESSENTIAL MEDICINE | NORTH |
| UNIVERSITY OF VERMONT AND STATE | ||||||||
| AGRICULTURAL COLLEGE 85 SOUTH | BURLINGTON | VT | 05405 | 030179440 | 501(C)(3) | $57,854 | ESSENTIAL MEDICINE | PROSPECT STREET |
| UNIVERSITY OF WASHINGTON ( UW ) | ||||||||
| 12455 COLLECTIONS DRIVE | CHICAGO | IL | 60693 | 916001537 | 501(C)(3) | $1,673,811 | ESSENTIAL MEDICINE, GLOBAL HEALTH PROGRAMS, OTHER, AND TECHNOLOGY, ANALYTICS AND MARKET INNOVATION | |
| VILLAGEREACH | ||||||||
| 2900 EASTLAKE AVE E SUITE 230 | SEATTLE | WA | 981023012 | 912088484 | 501(C)(3) | $1,271,766 | GLOBAL HEALTH PROGRAMS | |
| WALTER REED ARMY INSTITUTE OF RESEARCH | ||||||||
| US TREASURY 503 ROBERT GRANT AVE | SILVER SPRING | MD | 20910 | 520664528 | GOV | $1,550,593 | ESSENTIAL MEDICINE | |
| YALE UNIVERSITY | ||||||||
| GRANT AND CONTRACT FINANCIAL ADMIN | NEW HAVEN | CT | 065081873 | 060646973 | 501(C)(3) | $64,471 | GLOBAL HEALTH PROGRAMS | PO BOX 1873 |
| PVS | ||||||||
| 2201 WESTLAKE AVE SUITE 200 | SEATTLE | WA | 98121 | 830431851 | 501(C)(3) | $92,478 | OTHER | |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 52 | Total501c3OrgCnt |
| Total Other Org | 13 | TotalOtherOrgCnt |
Grants Other Asst To Indiv In US GrantsOtherAsstToIndivInUSGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Type | GRANT | GrantTypeTxt |
| Recipient | 1 | RecipientCnt |
| Cash Grant | $10,313 | CashGrantAmt |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART I, LINE 2: | FormAndLineReferenceDesc |
| Explanation | PATH HAS A SUBRECIPIENT POLICY AND PROCEDURES IN PLACE TO GUIDE THE WAY OUR PROJECT TEAMS MONITOR SUBRECIPIENTS. THIS INCLUDES BOTH FINANCIAL AND TECHNICAL MONITORING. PATH USES RISK ASSESSMENTS, REPORTING, SITE VISITS, REGULAR CONTACT, AND OTHER MEANS TO PROVIDE THE MONITORING REQUIRED BY FUNDERS AND TO ENSURE GOOD PROJECT STEWARDSHIP. THESE ACTIVITIES ALSO PROVIDE RESPONSIBLE ASSURANCE THAT THE SUBRECIPIENT ADMINISTERS FUNDS IN COMPLIANCE WITH LAWS, REGULATIONS, AND PRIME AWARD TERMS AND ACHIEVES PERFORMANCE GOALS. PATH HAS ESTABLISHED COMPREHENSIVE POLICIES AND PROCEDURES TO PROMOTE BEST BUSINESS PRACTICES AND ENSURE EFFICIENT AND EFFECTIVE INTERNAL CONTROL. THESE ARE COMBINED WITH AN INTERNAL AUDIT FUNCTION THROUGH WHICH PATH CONDUCTS AUDITS ON GRANT-FUNDED PROGRAMS TO ENSURE COMPLIANCE WITH REGULATORY REQUIREMENTS. | ExplanationTxt |
Schedule J IRS990ScheduleJ
| Field | Value | IRS element (for citing) |
|---|---|---|
| Idemnification Gross Up Pmts | Yes (X) | IdemnificationGrossUpPmtsInd |
| Housing Allowance Or Residence | Yes (X) | HousingAllowanceOrResidenceInd |
| Written Policy Ref T And E Expnss | Yes (1) | WrittenPolicyRefTAndEExpnssInd |
| Substantiation Required | Yes (1) | SubstantiationRequiredInd |
| Compensation Committee | Yes (X) | CompensationCommitteeInd |
| Independent Consultant | Yes (X) | IndependentConsultantInd |
| Compensation Survey | Yes (X) | CompensationSurveyInd |
| Board Or Committee Approval | Yes (X) | BoardOrCommitteeApprovalInd |
| Severance Payment | Yes (1) | SeverancePaymentInd |
| Supplemental Nonqual Rtr Plan | 0 | SupplementalNonqualRtrPlanInd |
| Equity Based Comp Arrngm | 0 | EquityBasedCompArrngmInd |
| Comp Based On Revenue Of Flng Org | 0 | CompBasedOnRevenueOfFlngOrgInd |
| Comp Bsd On Rev Related Orgs | 0 | CompBsdOnRevRelatedOrgsInd |
| Comp Bsd Net Earns Flng Org | 0 | CompBsdNetEarnsFlngOrgInd |
| Comp Bsd Net Earns Rltd Orgs | 0 | CompBsdNetEarnsRltdOrgsInd |
| Any Non Fixed Payments | Yes (1) | AnyNonFixedPaymentsInd |
| Initial Contract Exception | 0 | InitialContractExceptionInd |
Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (17 entries)
| TitleTitleTxt | Base Compensation Filing OrgBaseCompensationFilingOrgAmt | Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt | Bonus Filing OrganizationBonusFilingOrganizationAmount | Bonus Related OrganizationsBonusRelatedOrganizationsAmt | Other Compensation Filing OrgOtherCompensationFilingOrgAmt | Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt | Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt | Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt | Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt | Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt | Total Compensation Filing OrgTotalCompensationFilingOrgAmt | Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt | Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt | Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| STEPHEN BROWN DAVIS | ||||||||||||||
| PRESIDENT AND CEO | $480,557 | $0 | $78,315 | $0 | $1,800 | $0 | $33,600 | $0 | $30,402 | $0 | $624,674 | $0 | $0 | $0 |
| OLIVIA D POLIUS | ||||||||||||||
| CHIEF FINANCIAL OFFICER | $177,827 | $0 | $0 | $0 | $171,006 | $0 | $21,972 | $0 | $9,995 | $0 | $380,800 | $0 | $0 | $0 |
| JERRY KUO | ||||||||||||||
| CHIEF OF STRATEGIC FINANCE | $215,187 | $0 | $0 | $0 | $400 | $0 | $26,848 | $0 | $29,105 | $0 | $271,540 | $0 | $0 | $0 |
| BRIAN N NEVILLE | ||||||||||||||
| CHIEF OF ACCOUNTING | $222,837 | $0 | $0 | $0 | $840 | $0 | $25,743 | $0 | $8,967 | $0 | $258,387 | $0 | $0 | $0 |
| PRAVEEN RAJA | ||||||||||||||
| CHIEF OPERATING OFFICER | $372,545 | $0 | $0 | $0 | $35,995 | $0 | $28,983 | $0 | $10,854 | $0 | $448,377 | $0 | $0 | $0 |
| DAVID C KASLOW | ||||||||||||||
| VP - ESSENTIAL MEDICNES | $381,740 | $0 | $0 | $0 | $1,800 | $0 | $33,600 | $0 | $32,581 | $0 | $449,721 | $0 | $0 | $0 |
| JEFFREY D BERNSON | ||||||||||||||
| VP - TECH, ANALYTICS, & MRKT INNOV. | $250,526 | $0 | $48,088 | $0 | $74,760 | $0 | $30,428 | $0 | $26,919 | $0 | $430,721 | $0 | $0 | $0 |
| DAVID W FLEMING | ||||||||||||||
| VP - PUBLIC HEALTH | $299,264 | $0 | $0 | $0 | $2,419 | $0 | $33,600 | $0 | $14,712 | $0 | $349,995 | $0 | $0 | $0 |
| ELAINE L GIBBONS | ||||||||||||||
| VP - GLOBAL ENGAGEMENT | $248,319 | $0 | $0 | $0 | $1,720 | $0 | $32,171 | $0 | $40,044 | $0 | $322,254 | $0 | $0 | $0 |
| MOLLI M BARNES | ||||||||||||||
| CHIEF PEOPLE OFFICER | $216,617 | $0 | $0 | $0 | $220 | $0 | $24,805 | $0 | $23,067 | $0 | $264,709 | $0 | $0 | $0 |
| ERICA JANE SESSLE | ||||||||||||||
| CHIEF OF STAFF | $213,096 | $0 | $0 | $0 | $1,800 | $0 | $25,647 | $0 | $11,234 | $0 | $251,777 | $0 | $0 | $0 |
| SABRINA L POWERS | ||||||||||||||
| GENERAL COUNSEL | $160,935 | $0 | $0 | $0 | $700 | $0 | $19,552 | $0 | $12,187 | $0 | $193,374 | $0 | $0 | $0 |
| TRAD M HATTON | ||||||||||||||
| COUNTRY DIRECTOR | $135,223 | $0 | $0 | $0 | $198,189 | $0 | $17,214 | $0 | $32,569 | $0 | $383,195 | $0 | $0 | $0 |
| JAMES B MCKENNA | ||||||||||||||
| DEPUTY DIRECTOR | $164,480 | $0 | $0 | $0 | $125,801 | $0 | $23,317 | $0 | $54,308 | $0 | $367,906 | $0 | $0 | $0 |
| ASHLEY J BIRKETT | ||||||||||||||
| GLOBAL HEAD, MALARIA VACCINES | $309,050 | $0 | $0 | $0 | $990 | $0 | $30,310 | $0 | $29,092 | $0 | $369,442 | $0 | $0 | $0 |
| BRUCE LAMONT INNIS | ||||||||||||||
| GLOBAL HEAD, RESPIRATORY INFECTIONS | $319,784 | $0 | $0 | $0 | $840 | $0 | $33,600 | $0 | -$708 | $0 | $353,516 | $0 | $0 | $0 |
| JOHN O KONZ | ||||||||||||||
| GLOBAL HEAD, FINANCIAL MANAGEMENT | $312,128 | $0 | $0 | $0 | $840 | $0 | $33,600 | $0 | $27,568 | $0 | $374,136 | $0 | $0 | $0 |
Supplemental Information Detail SupplementalInformationDetail (3 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| PART I, LINE 1A | HOUSING ALLOWANCES & TAX INDEMNIFICATIONS ARE ONLY PROVIDED TO THOSE INDIVIDUALS WHO ARE EXPATRIATE EMPLOYEES. ALL BENEFIT PAYMENTS ARE MADE ACCORDING TO OUR EXPATRIATE POLICY. PART I, LINE 3: PATH ENGAGES WITH A CONSULTING FIRM TO REVIEW THE COMPENSATION FOR EACH OF THE SENIOR MANAGEMENT POSITIONS. PATH PROVIDES AN ANNUAL SALARY ADJUSTMENT EACH JANUARY BASED ON THE OVERALL LABOR MARKET MOVEMENT. |
| PART I, LINE 4A | THE FOLLOWING EMPLOYEES RECEIVED SEVERANCE PAYMENTS IN 2019: - OLIVIA POLIUS $163,910 |
| PART I, LINE 7 | BONUS COMPENSATION HAS BEEN REFLECTED IN PART II, COLUMN (B)(II). |
Schedule M IRS990ScheduleM
Securities Publicly Traded SecuritiesPubliclyTradedGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Non Cash Checkbox | Yes (X) | NonCashCheckboxInd |
| Contribution | 18 | ContributionCnt |
| Noncash Contributions Rpt F990 | $219,075 | NoncashContributionsRptF990Amt |
| Method Of Determining Revenues | FMV | MethodOfDeterminingRevenuesTxt |
Other Non Cash Contri Table OtherNonCashContriTableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Non Cash Checkbox | Yes (X) | NonCashCheckboxInd |
| Desc | SOFTWARE/SUPP. | Desc |
| Contribution | 5 | ContributionCnt |
| Noncash Contributions Rpt F990 | $4,124,378 | NoncashContributionsRptF990Amt |
| Method Of Determining Revenues | COST | MethodOfDeterminingRevenuesTxt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Any Property That Must Be Held | 0 | AnyPropertyThatMustBeHeldInd |
| Review Process Unusual NC Gifts | Yes (1) | ReviewProcessUnusualNCGiftsInd |
| Third Parties Used | 0 | ThirdPartiesUsedInd |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART I, COLUMN (B): | FormAndLineReferenceDesc |
| Explanation | THIS COLUMN REFLECTS THE NUMBER OF CONTRIBUTIONS. | ExplanationTxt |
Schedule O IRS990ScheduleO
Supplemental Information Detail SupplementalInformationDetail (11 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| FORM 990, PART III, LINE 1, DESCRIPTION OF ORGANIZATION MISSION: | PATH IS A GLOBAL ORGANIZATION THAT WORKS TO ACCELERATE HEALTH EQUITY BY BRINGING TOGETHER PUBLIC INSTITUTIONS, BUSINESSES, SOCIAL ENTERPRISES, AND INVESTORS TO SOLVE THE WORLD'S MOST PRESSING HEALTH CHALLENGES. WITH EXPERTISE IN SCIENCE, HEALTH, ECONOMICS, TECHNOLOGY, ADVOCACY, AND DOZENS OF OTHER SPECIALTIES, PATH DEVELOPS AND SCALES UP SOLUTIONS-INCLUDING VACCINES, DRUGS, DEVICES, DIAGNOSTICS, AND INNOVATIVE APPROACHES TO STRENGTHENING HEALTH SYSTEMS WORLDWIDE. SINCE 2011, PATH AND OUR PARTNERS AND SUPPORTERS HAVE IMPROVED HEALTH FOR MORE THAN 150 MILLION PEOPLE ON AVERAGE EACH YEAR. THE LARGEST INVESTMENTS IN PATH'S PROGRAMMATIC WORK IN 2019 WERE ORGANIZED INTO THREE PRIMARY PORTFOLIOS: GLOBAL HEALTH PROGRAMS; ESSENTIAL MEDICINES; AND TECHNOLOGY, ANALYTICS, AND MARKET INNOVATION. SEE BELOW FOR DESCRIPTIONS OF THESE PROGRAMS. |
| FORM 990, PART III, LINE 4A, DESCRIPTION OF PROGRAM SERVICE: | IN UKRAINE, PATH LEADS THE USAID-FUNDED SERVING LIFE PROJECT, WHICH REDUCES TB, HIV, AND HEPATITIS C TRANSMISSION IN PRETRIAL DETENTION CENTERS, PRISONS, POST-PRISON SETTINGS, AND THE COMMUNITY. STRATEGIES INCLUDE INCREASING CASE DETECTION, STRENGTHENING LINKAGES TO CARE, AND EMPLOYING A CASE-MANAGEMENT APPROACH TO ENSURE TREATMENT COMPLETION. IN 2019, WE WORKED IN 12 REGIONS IN 75 PRETRIAL DETENTION CENTERS, PRISON COLONIES, AND CORRECTIONAL CENTERS, AND 12 PROBATION CENTERS. WE TESTED APPROXIMATELY 30,000 PEOPLE FOR HIV, LINKED AROUND 3,000 NEWLY IDENTIFIED PLHIV TO TREATMENT, AND SUPPORTED ABOUT 2,500 PEOPLE IN PRISON ON HIV TREATMENT. IN 2019, WE ALSO PARTNERED WITH THE MINISTRY OF JUSTICE TO LAUNCH A PILOT PROGRAM TO PROVIDE OPIOID-SUBSTITUTION THERAPY TO PEOPLE WHO INJECT DRUGS, THE FIRST TIME THIS INTERVENTION HAS BEEN PROVIDED IN A PRISON IN UKRAINE. IN ANOTHER ADVANCEMENT, WE ROLLED OUT THE USE OF A SMART PILL BOX THAT REMINDS PATIENTS TO TAKE THEIR TB MEDICATION AND NOTIFIES PROVIDERS IF DOSES ARE MISSED, RESULTING IN 90% TREATMENT COMPLETION AMONG PATIENTS USING THIS TECHNOLOGY. WE WILL CONTINUE TO BUILD ON THESE SUCCESSES AS A PARTNER UNDER THE UNITAID-FUNDED ADHERENCE SUPPORT COALITION TO END TB PROJECT, LAUNCHED IN 2019. FOR MORE INFORMATION ON OUR WORK IN UKRAINE, SEE THE COUNTRY PROGRAMS SECTION. IN VIETNAM, PATH CONTINUED TO PILOT INNOVATIONS IN HIV. IN 2019, WE EQUIPPED SOCIAL ENTERPRISES AND PRIVATE CLINICS LED BY KEY POPULATIONS TO GENERATE DEMAND FOR AND PROVIDE HIV SERVICES. INNOVATIVE ONLINE CHAT BOTS OFFERED INFORMATION ON HIV SELF TESTING (HIVST) AND PRE-EXPOSURE PROPHYLAXIS (PREP); CARE PROVIDERS THEN SERVED THESE CLIENTS OFFLINE IN COMMUNITIES OR AT CLINICS. PATH ALSO ENGAGED THE GOVERNMENT OF VIETNAM TO SCALE UP NEW MODELS OF HIV TESTING, INCLUDING EXPANDING ACCESS TO HIV LAY- AND SELF-TESTING AND PARTNER NOTIFICATION SERVICES. THE PROJECT TESTED APPROXIMATELY 50,000 PEOPLE IN 2019. WORKING AGAIN WITH THE GOVERNMENT AND KEY POPULATION SERVICE PROVIDERS, PATH INTRODUCED A VARIETY OF SERVICE MODELS TO RAPIDLY SCALE UP PREP NATIONWIDE; IN 2019 ALONE, WE DOUBLED THE NUMBER OF PEOPLE ON PREP. PATH ALSO FOCUSED ON TB CONTROL. IN 2019, THE BREATH FOR LIFE PROJECT WORKED WITH VIETNAM'S NATIONAL TUBERCULOSIS PROGRAM TO DEVELOP AND TEST STANDARD OPERATING PROCEDURES TO ADDRESS THE SPECIMEN COLLECTION CHALLENGES THAT CONTRIBUTE TO LOW DETECTION OF TB IN CHILDREN. OUR EFFORTS RESULTED IN UPDATED NATIONAL GUIDELINES THAT FACILITATED COUNTRYWIDE SCALE-UP OF STOOL XPERT TESTING FOR TB DIAGNOSIS AMONG CHILDREN. IN INDIA, PATH DEVELOPED TOOLS AND APPLICATIONS TO ENHANCE MONITORING OF HIV SERVICE DELIVERY THROUGH IMPROVED DATA QUALITY AND AUTOMATED DATA COMPILATION. TO IMPROVE TB SERVICES, WE PILOTED ARTIFICIAL INTELLIGENCE TO STREAMLINE CHEST X-RAY READINGS, ENABLING QUICKER DIAGNOSIS AND INITIATION ON TB TREATMENT. FURTHER, WE WORKED CLOSELY WITH THE NATIONAL TB PROGRAM TO DEVELOP PUBLIC-PRIVATE PARTNERSHIP GUIDELINES, AND WE CONTINUED ENGAGING THE PRIVATE SECTOR TO LINK DRUG-RESISTANT TB PATIENTS TO PUBLIC-SECTOR CARE. IN TANZANIA, PATH AND OUR PARTNERS DEVELOPED A MOBILE PHONE APPLICATION THAT ENABLED ALMOST 229,900 PEOPLE TO SELF-SCREEN FOR TB. IN ZAMBIA, PATH CONTINUED TO IMPLEMENT THE ERADICATE TB PROJECT, SUPPORTING 249 HEALTH FACILITIES ACROSS SIX PROVINCES. THE PROJECT TESTED MORE THAN 125,000 PEOPLE FOR TB AND INITIATED MORE THAN 8,000 PEOPLE ON TREATMENT. FOR MORE INFORMATION, SEE THE COUNTRY PROGRAMS SECTION. ALSO IN 2019, PATH BEGAN WORK ON A NEW TB PROJECT IN CENTRAL ASIA THAT PROVIDES CLINICAL TECHNICAL SUPPORT AND DRUG SAFETY MONITORING TO NATIONAL TB PROGRAMS IN TAJIKISTAN, KAZAKHSTAN, AND UZBEKISTAN. MATERNAL, NEWBORN, AND CHILD HEALTH AND NUTRITION: PATH WORKS WITH PARTNERS TO IMPROVE MATERNAL, NEWBORN, AND CHILD HEALTH AND NUTRITION AROUND THE WORLD. TOGETHER WE DEVELOP, ADAPT, AND SCALE TECHNOLOGIES AND APPROACHES TO REDUCE ILLNESS AND DEATH AND GIVE CHILDREN THE BEST POSSIBLE START IN LIFE. IN 2019, PATH CONTINUED TO EXPAND OUR GLOBAL AND NATIONAL LEADERSHIP IN EARLY CHILDHOOD DEVELOPMENT (ECD). WITH PATH SUPPORT, THE GOVERNMENTS OF ETHIOPIA, KENYA, MOZAMBIQUE, AND ZAMBIA CONTINUED TO INCORPORATE ECD SERVICES INTO BASIC HEALTH CARE. THIS PIONEERING WORK FOCUSES ON BUILDING AN ENABLING LEADERSHIP AND POLICY ENVIRONMENT WHILE SUPPORTING AND STRENGTHENING THE CAPACITY OF HEALTH SYSTEMS AND HEALTH SERVICE PROVIDERS. ALONG WITH WHO, UNICEF, THE WORLD BANK, AND OTHERS, PATH HELPED ADVANCE THE NURTURING CARE FOR ECD FRAMEWORK, WHICH OFFERS A STRUCTURE FOR COUNTRIES TO ADOPT, ADAPT, AND SCALE ECD SERVICES. IN PARTNERSHIP WITH THE AFRICAN POPULATION AND HEALTH RESEARCH CENTER, WE LAUNCHED A RANDOMIZED CONTROL TRIAL OF ECD INTERVENTIONS IN KENYA. WITH HARVARD UNIVERSITY, WE DESIGNED A LARGE-SCALE EVALUATION IN MOZAMBIQUE. PATH CONTINUED EFFORTS TO ENSURE THAT ALL INFANTS RECEIVE HUMAN MILK. OUR WORK CENTERS AROUND BREASTFEEDING PROMOTION, INCLUDING THE PROVISION OF SAFE DONOR MILK THROUGH HUMAN MILK BANKS. IN 2019, PATH LAUNCHED STRENGTHENING HUMAN MILK BANKING: A RESOURCE TOOLKIT FOR ESTABLISHING AND OPERATING HUMAN MILK BANK PROGRAMS, THE FIRST-EVER STANDARD TO ENSURE QUALITY AND SAFETY. AMONG OTHER EFFORTS, PATH WORKED WITH THE MINISTRY OF HEALTH (MOH) IN KENYA TO LAUNCH THE FIRST HUMAN MILK BANK IN THE EAST AFRICAN REGION AND CONDUCTED AN EVALUATION TO ASSESS OUTCOMES. IN GHANA, THE MAKING EVERY BABY COUNT INITIATIVE STRENGTHENED LEADERSHIP AND CAPACITY AT THE NATIONAL AND LOCAL LEVELS TO MANAGE AND SUSTAIN BEST PRACTICES IN NEWBORN CARE. BY 2019, PATH HAD TRAINED MORE THAN 3,600 FRONTLINE HEALTH WORKERS IN IMPROVED NEWBORN CARE, HELPED DRIVE ADVOCACY AND POLICY THROUGH THE GHANA NATIONAL NEWBORN SUBCOMMITTEE, AND PARTNERED WITH THE GHANA HEALTH SERVICE ON ITS NEWBORN ACTION PLAN TO REDUCE NEONATAL MORTALITY RATES. RECOGNIZING THAT NUTRITION IS AFFECTED BY A VARIETY OF ECONOMIC AND ENVIRONMENTAL FACTORS, PATH'S NUTRITION TEAM CONTINUED TO DRIVE NOVEL APPROACHES TO ADDRESS THE MASSIVE BURDEN OF MALNUTRITION IN COMMUNITIES AROUND THE WORLD. WE ENGAGED STAKEHOLDERS WITH EXPERTISE SPANNING GLOBAL HEALTH, DEVELOPMENT, AND THE ENVIRONMENT, FROM BOTH THE PUBLIC AND PRIVATE SECTORS. PATH CONTINUED TO LEAD A CONSORTIUM OF FIVE ORGANIZATIONS IN A PROJECT KNOWN AS MAXIMISING THE QUALITY OF SCALING UP NUTRITION PLUS (MQSUN+). IN 2019, MQSUN+ SUPPORTED THE DEVELOPMENT OF A MULTISECTORAL NUTRITION PLAN FOR TAJIKISTAN AND COSTED MULTISECTORAL NUTRITION PLANS FOR AFGHANISTAN, GUINEA, SOMALIA, TOGO, AND YEMEN. MQSUN+ ALSO SUPPORTED EFFORTS TO PROVIDE STRATEGIC DIRECTION TOWARD THE NEXT PHASE OF THE "SCALING UP NUTRITION" MOVEMENT AND CONTINUED TO ADVANCE AND SUPPORT THE TRACKING OF FINANCIAL AND NONFINANCIAL COMMITMENTS TO NUTRITION. OTHER ACTIVITIES IN 2019 INCLUDED PARTNERING WITH THE NATURE CONSERVANCY, DUKE UNIVERSITY, AND THE INTERNATIONAL FOOD POLICY RESEARCH INSTITUTE ON USE OF ALTERNATIVE PROTEINS; THIS WORK WAS FUNDED BY THE ROCKEFELLER FOUNDATION. WE ALSO WORKED WITH HARVEST PLUS TO EXPAND THE REACH OF BIOFORTIFIED CROPS. WE CONTINUED TO DRIVE MULTISECTORAL COLLABORATION IN 2019 THROUGH THE BRIDGE COLLABORATIVE, A TRAILBLAZING, CROSS-DISCIPLINARY EFFORT TO ENGAGE MORE THAN 150 LEADING TECHNICAL EXPERTS FROM THE HEALTH, DEVELOPMENT, AND ENVIRONMENTAL SECTORS TO ADDRESS HUMAN AND PLANETARY HEALTH. IN CONJUNCTION WITH THE WILDLIFE CONSERVATION SOCIETY AND THE NATURE CONSERVANCY, THE BRIDGE COLLABORATIVE PUBLISHED SEVERAL NEW PAPERS AND HELD SEVERAL MEETINGS ON FOOD SYSTEMS AND THE INTERSECTION OF HUMAN AND PLANETARY HEALTH. IN 2019, PATH STAFF MEMBERS PRESENTED AT KEY GLOBAL AND NATIONAL MEETINGS AND AUTHORED, EDITED, AND CONTRIBUTED TO VARIOUS HIGH-PROFILE PEER-REVIEWED JOURNAL ARTICLES, BOOK CHAPTERS, GLOBAL REPORTS, AND SYSTEMATIC REVIEWS. THESE EFFORTS ADVANCED THINKING ON BROAD, EFFECTIVE SOLUTIONS TO THE MOST PRESSING CHALLENGES IN MATERNAL, NEWBORN, AND CHILD HEALTH AND NUTRITION. SEXUAL AND REPRODUCTIVE HEALTH: PATH'S WORK IN SEXUAL AND REPRODUCTIVE HEALTH IS GUIDED BY THE KEY PRINCIPLES OF CHOICE, EQUITY, AND DIGNITY FOR ALL WOMEN. BECAUSE WE UNDERSTAND THE COMPLEX SOCIAL, BEHAVIORAL, AND GENDER DIMENSIONS OF WOMEN'S REPRODUCTIVE HEALTH, WE BUILD EVIDENCE AROUND TOOLS AND SERVICES THAT ARE BEST SUITED TO ADDRESS WOMEN'S DIVERSE NEEDS AND CIRCUMSTANCES. WE SPECIALIZE IN REDUCING BARRIERS TO ACCESS. |
| FORM 990, PART III, LINE 4A, DESCRIPTION OF PROGRAM SERVICE: | IN 2019, PATH CONTINUED TO CHAMPION THE RIGHT OF WOMEN TO MANAGE THEIR OWN SEXUAL AND REPRODUCTIVE HEALTH BY CREATING AND ADVANCING IMPROVED TOOLS AND PRACTICES THAT MAKE WOMEN'S SELF-CARE POSSIBLE. AN INTEGRATED APPROACH TO WOMEN'S HEALTH INCLUDES ATTENTION TO CONTRACEPTION, CERVICAL AND BREAST CANCER, SEXUALLY TRANSMITTED INFECTIONS, AND A WOMAN'S RIGHT TO DECIDE WHETHER AND WHEN TO BECOME A MOTHER. AMONG THE RECENT WOMAN-INITIATED PRODUCTS INTRODUCED BY PATH ARE AN ALL-IN-ONE INJECTABLE CONTRACEPTIVE THAT CAN BE SELF-ADMINISTERED AND A VAGINAL SELF-SAMPLING KIT FOR HUMAN PAPILLOMAVIRUS (HPV) TESTING IN CERVICAL CANCER SCREENING PROGRAMS, AS DESCRIBED BELOW. PATH'S RESEARCH AND COORDINATION TO EXPAND ACCESS TO THE INJECTABLE CONTRACEPTIVE SUBCUTANEOUS DMPA (DMPA-SC, OR SAYANA PRESS) CONTINUED IN 2019, PRIMARILY THROUGH THE SELF-INJECTION BEST PRACTICES AND DMPA-SC ACCESS COLLABORATIVE PROJECTS. OUR SELF-INJECTION PROJECT IN UGANDA TOOK A USER-CENTERED APPROACH TO DEVELOP AND INTRODUCE MODELS FOR CONTRACEPTIVE SELF-INJECTION AND DISSEMINATED INFORMATION ON HOW THE PRACTICE CAN BE IMPLEMENTED AT SCALE. MORE THAN 7,000 WOMEN SELF-INJECTED DMPA-SC ACROSS FOUR DISTRICTS THROUGH THIS PROGRAM. THE DMPA-SC ACCESS COLLABORATIVE CONTINUED WORKING WITH MINISTRIES OF HEALTH AND PARTNERS ACROSS SECTORS IN SEVEN COUNTRIES TO FACILITATE DMPA-SC INTRODUCTION AS WELL AS SCALE-UP PLANNING FOR A RANGE OF CONTRACEPTIVE OPTIONS. IN 2019, THE COLLABORATIVE PROVIDED TECHNICAL ASSISTANCE TO ENSURE IMPLEMENTATION OF EACH COUNTRY'S TOTAL MARKET PLAN. THE COLLABORATIVE FACILITATED LEARNING ACROSS COUNTRIES BY EXCHANGING INFORMATION, RESULTS, AND LESSONS LEARNED; TROUBLESHOOTING CHALLENGES; AND ACCELERATING THE ADOPTION OF BEST PRACTICES. PATH WORKED WITH GLOBAL AND COUNTRY PARTNERS TO IMPROVE THE PREVENTION, DETECTION, AND TREATMENT OF CERVICAL PRECANCER, WHICH IS CAUSED BY INFECTION WITH HPV. WE CONTINUED OUR PARTNERSHIP WITH THE MINISTRIES OF HEALTH IN GUATEMALA AND HONDURAS TO SUPPORT THE SCALE-UP OF HPV TESTING IN THE PUBLIC SECTOR. WE PROVIDED TECHNICAL SUPPORT FOR PROCUREMENT OF TESTS, SUPPORTED ADVOCACY AND DISSEMINATION EVENTS, AND MADE PROGRESS TOWARD TRANSITIONING LEADERSHIP OF THE PROGRAM TO THE MINISTRIES AS THE PROJECT WAS IN ITS FINAL YEAR. WE ALSO EVALUATED FOLLOW-UP AND TREATMENT STRATEGIES TO ENSURE WOMEN RECEIVE APPROPRIATE, COMPREHENSIVE CARE. PATH PARTICIPATED IN WHO'S CALL FOR GLOBAL CERVICAL CANCER ELIMINATION BY HELPING SHAPE STRATEGIES FOR LOW- AND MIDDLE-INCOME COUNTRIES. IN MYANMAR, WE ENGAGED WITH THE MOH AND OTHER STAKEHOLDERS TO DESIGN A CERVICAL CANCER CONTROL PLAN. A PATH-LED CONSORTIUM ALSO WORKED CLOSELY WITH THE MOH TO STRENGTHEN THE KNOWLEDGE, CAPACITY, AND COORDINATION OF DECISION-MAKERS, SERVICE PROVIDERS, AND COMMUNITY MEMBERS TO UNDERSTAND SEXUAL AND REPRODUCTIVE HEALTH SERVICES AND RIGHTS AND TO INFLUENCE THE DEVELOPMENT AND IMPLEMENTATION OF RELATED POLICIES. TO COMBAT BREAST CANCER, WE WORKED IN PERU WITH THE NATIONAL AND REGIONAL CANCER INSTITUTES AND OTHER STAKEHOLDERS TO IMPLEMENT A MODEL FOR EARLY DETECTION OF BREAST CANCER APPROPRIATE AND FEASIBLE FOR LOW- AND MIDDLE-RESOURCE SETTINGS. WE BUILT THE CAPACITY OF HEALTH PROFESSIONALS TO IMPLEMENT THIS MODEL AND SHARED EVIDENCE WITH MOH REPRESENTATIVES FROM EL SALVADOR, GUATEMALA, HONDURAS, AND NICARAGUA. WE ALSO CONDUCTED ADVOCACY AMONG HEALTH OFFICIALS TO ENSURE BREAST CANCER REMAINS ON THE AGENDA AND WOMEN RECEIVE SCREENING AND TREATMENT EVEN IN THE ABSENCE OF MAMMOGRAPHY SERVICES. PATH CONTINUED TO SERVE AS THE SECRETARIAT FOR THE REPRODUCTIVE HEALTH SUPPLIES COALITION, A GLOBAL PARTNERSHIP OF MORE THAN 400 PUBLIC AND PRIVATE ENTITIES AND NGOS WORKING TO EXPAND ACCESS TO CRITICAL SEXUAL AND REPRODUCTIVE HEALTH AND FAMILY PLANNING SUPPLIES AND SERVICES. NONCOMMUNICABLE DISEASES: PATH IS AT THE FOREFRONT OF THE FIGHT AGAINST NONCOMMUNICABLE DISEASES (NCDS), INCLUDING DIABETES AND CARDIOVASCULAR DISEASE, IN LOW-RESOURCE SETTINGS WORLDWIDE. THE BURDEN OF THESE DISEASES IS RISING DISPROPORTIONATELY AMONG LOW- AND MIDDLE-INCOME COUNTRIES AND POPULATIONS. IN 2019, PATH CONTINUED TO SERVE AS THE SECRETARIAT OF THE COALITION FOR ACCESS TO NCD MEDICINES AND PRODUCTS. THIS GLOBAL, MULTISECTORAL COALITION IS DEDICATED TO INCREASING ACCESS TO NCD MEDICINES AND HEALTH PRODUCTS IN LOW- AND MIDDLE-INCOME COUNTRIES. IN ADDITION TO GLOBAL ADVOCACY EFFORTS, THE COALITION FOCUSED ON EAST AFRICA. AMONG OTHER ACTIVITIES, PATH CO-LED A MEETING WITH THE EAST AFRICA COMMUNITY SECRETARIAT TO BEGIN DEVELOPING A REGIONAL FRAMEWORK FOR NCDS. IN COLLABORATION WITH THE KENYA MOH AND LOCAL STAKEHOLDERS, PATH CONTINUED TO REFINE THE NCD NAVIGATOR, A FIRST-OF-ITS-KIND DIGITAL MANAGEMENT INFORMATION SYSTEM THAT PROVIDES REAL-TIME DATA ON NCD PROGRAMMING. OTHER ACHIEVEMENTS INCLUDED AN END-TO-END NCD SUPPLY CHAIN ASSESSMENT IN KENYA THAT WILL INFORM SUPPLY CHAIN STRENGTHENING EFFORTS. IN 2019, PATH BEGAN ADDRESSING THE GROWING NCD BURDEN IN GHANA BY LEVERAGING THE WORK DONE IN KENYA AND APPLYING THE NCD NAVIGATOR TO THE LOCAL CONTEXT. WE CONDUCTED A SITUATIONAL ANALYSIS AND DEVELOPED A PROTOCOL FOR A SUPPLY CHAIN ASSESSMENT (TO BE IMPLEMENTED IN 2020). ALSO IN GHANA, PATH LAUNCHED THE HEALTHY HEART AFRICA PROJECT. IN PARTNERSHIP WITH THE GHANA HEALTH SERVICE, THE PROJECT WORKS IN THE ASHANTI REGION TO SUPPORT HYPERTENSION SCREENING AND LINKAGES TO CARE. IN 2019, THE PROGRAM CONDUCTED MORE THAN 20,000 BLOOD PRESSURE SCREENINGS AND DIAGNOSED MORE THAN 1,200 PEOPLE WITH HYPERTENSION, CONTRIBUTING TO NATIONAL TESTING EFFORTS. IN VIETNAM, PATH BUILT ON THE PREVIOUS COMMUNITIES FOR HEALTHY HEARTS PROJECT AND ADAPTED THE MODEL IN 2019 TO INCLUDE DIABETES AND HYPERTENSION. USING LESSONS LEARNED AND CAPACITY STRENGTHENING ACTIVITIES, THE MODEL WAS SCALED UP NATIONALLY. WORKING CLOSELY WITH THE MOH AND A PROVINCIAL GOVERNMENT, WE SCREENED 10,000 PEOPLE AND LINKED 6,000 PEOPLE TO CARE. PATH ALSO COLLABORATED WITH THE MOH TO CREATE A DIGITAL ROAD MAP FOR MANAGING NCDS IN VIETNAM. IN SENEGAL, PATH IMPLEMENTED THE BETTER HEARTS BETTER CITIES PROJECT TO IMPROVE THE HYPERTENSION CONTROL RATE IN DAKAR. MORE INFORMATION CAN BE FOUND IN THE COUNTRY PROGRAMS SECTION. PATH ALSO IMPLEMENTED A HYPERTENSION SCREENING PROJECT IN MUMBAI, INDIA, IN PARTNERSHIP WITH RESOLVE TO SAVE LIVES. THE PROJECT USES A PRIVATE-SECTOR ENGAGEMENT MODEL. FINALLY, PATH LED AND CONTRIBUTED TO CONVENINGS TO RAISE AWARENESS OF NCDS AND ORCHESTRATE ACTION TO IMPROVE ACCESS TO PREVENTION AND CARE. HEALTH SYSTEMS INNOVATION AND DELIVERY: PATH'S HEALTH SYSTEMS INNOVATION AND DELIVERY PROGRAM STRENGTHENS HEALTH SYSTEMS AND ENHANCES COUNTRY CAPACITY FOR DATA-DRIVEN DECISION-MAKING. OUR PORTFOLIO SERVES AS AN ORGANIZING MECHANISM FOR PATH PROJECTS, INITIATIVES, AND UNITS THAT STRENGTHEN HEALTH SYSTEMS. THE HEALTH SYSTEMS ANALYTICS UNIT PROMOTES SYSTEMS THINKING; WITHIN AND OUTSIDE OF PATH, THIS UNIT LEADS COMPLEX EVALUATIONS OF HEALTH PROGRAMS, ENGAGES IN IMPLEMENTATION SCIENCE RESEARCH, FACILITATES HEALTH TECHNOLOGY INTRODUCTION AND SCALE-UP, AND WORKS TO IMPROVE DATA QUALITY AND USE FOR DECISION-MAKING. IN 2019, AS PART OF THE GLOBAL FUND'S PROSPECTIVE COUNTRY EVALUATIONS, THE UNIT EVALUATED THE GLOBAL FUND'S BUSINESS MODEL IN THE DRC, GUATEMALA, AND UGANDA. STAFF ENGAGED IN NETWORK ANALYSES TO INFORM THE OPTIMAL STRUCTURE AND FUNCTION OF VARIOUS COALITIONS AND INFORMAL AND FORMAL NETWORKS. THE HEALTH SYSTEMS STRENGTHENING IMPACT TEAM CONTINUED TO SERVE AS A HUB FOR STAFF WORKING IN HEALTH SYSTEMS. THE TEAM PLANNED FUTURE WORK IN STRENGTHENING URBAN HEALTH SYSTEMS, IMPROVING COMMUNITY-LEVEL DATA USE, AND DEVELOPING RESOURCES FOR SUCCESSFUL INTRODUCTION AND SCALE-UP OF INTERVENTIONS AND TECHNOLOGIES. THIS TEAM ALSO DEVELOPED PATH'S PRIMARY HEALTH CARE STRATEGY. THE GLOBAL HEALTH SECURITY TEAM CONTINUED TO INNOVATE FOR THE PREVENTION, DETECTION, AND CONTROL OF INFECTIOUS DISEASE OUTBREAKS. WITH SUPPORT FROM THE US CENTERS FOR DISEASE CONTROL AND PREVENTION, THE TEAM WORKED WITH NATIONAL LEADERS IN THE DRC, SENEGAL, TANZANIA, AND VIETNAM TO STRENGTHEN THEIR PUBLIC HEALTH SYSTEMS AND BUILD THEIR CAPACITY IN EPIDEMIC PREPAREDNESS AND RESPONSE. THE TEAM ALSO WORKED AS A MAJOR SUBGRANTEE ON THE USAID-SUPPORTED INFECTIOUS DISEASE DETECTION & SURVEILLANCE PROJECT. THIS PROJECT WORKS TO IMPROVE THE DETECTION OF HIGH-PRIORITY INFECTIOUS DISEASES AND IDENTIFICATION OF ANTIMICROBIAL RESISTANCE THROUGH IMPROVED DIAGNOSTIC AND SURVEILLANCE SYSTEMS. OUR CROSS-ORGANIZATIONAL IMPACT TEAM FOR EPIDEMIC PREPAREDNESS AND RESPONSE CONTINUED TO BE AT THE FOREFRONT OF THE EBOLA RESPONSE IN THE DRC, ENHANCING SURVEILLANCE, DETECTION, AND RESOURCE MOBILIZATION. OTHER EFFORTS INCLUDED STRENGTHENING ELECTRONIC HEALTH INFORMATION SYSTEMS, ADVANCING NOVEL VACCINE PLATFORMS, PREPARING MEDICAL COUNTERMEASURES FOR PANDEMIC INFLUENZA, AND DEFINING PATH'S ROLE IN COMBATING ANTIMICROBIAL RESISTANCE. |
| FORM 990, PART III, LINE 4A, DESCRIPTION OF PROGRAM SERVICE: | COUNTRY PROGRAMS: PATH'S COUNTRY PROGRAMS SUPPORT WORK RANGING FROM SMALL-SCALE PILOTS TO LARGE, MULTICOUNTRY EFFORTS. IN 2019, WE OPERATED FULL-SCALE "COUNTRY" OFFICES IN THE DRC, ETHIOPIA, INDIA, KENYA, MYANMAR, SENEGAL, TANZANIA, UGANDA, UKRAINE, VIETNAM, AND ZAMBIA, AS WELL AS SMALLER "PROJECT" OFFICES IN MANY OTHER COUNTRIES. EXAMPLES THIS YEAR FOCUS ON SENEGAL, UKRAINE, AND ZAMBIA. IN SENEGAL, PATH WORKS CLOSELY WITH THE GOVERNMENT TO ACCELERATE PROGRESS TOWARD HEALTH SYSTEM MILESTONES. WE DO THIS IN PART BY BUILDING A CULTURE OF DATA USE. THE MACEPA PROGRAM, DESCRIBED EARLIER, HAS WORKED WITH SENEGAL'S MINISTRY OF HEALTH AND SOCIAL ACTION (MOHSA) AND NATIONAL MALARIA CONTROL PROGRAM SINCE 2010. IN 2019, MACEPA PROVIDED TECHNICAL ASSISTANCE IN DATA QUALITY AND DATA-DRIVEN DECISION-MAKING, OPERATIONAL RESEARCH, DEVELOPMENT OF NATIONAL POLICIES, AND COLLABORATION ON CROSS-BORDER ISSUES WITH NEIGHBORING COUNTRIES; FOR INSTANCE, PATH SUPPORTED COORDINATED PLANNING BETWEEN SENEGAL AND THE GAMBIA FOR THE DEVELOPMENT OF A SHARED DATA PLATFORM AND THE MASS DISTRIBUTION OF LONG-LASTING INSECTICIDE-TREATED BEDNETS. DURING 2019, PATH'S GLOBAL HEALTH SECURITY TEAM, ALSO DESCRIBED EARLIER, FOCUSED IN SENEGAL ON STRENGTHENING LABORATORY, SURVEILLANCE, AND INFORMATION SYSTEMS, AND ON PREVENTING ANTIMICROBIAL RESISTANCE. IN 2019, PATH SUPPORTED THE MOHSA TO IMPROVE ELECTRONIC REPORTING FROM HOSPITALS. WE ALSO SUPPORTED PUBLICATION OF KEY POLICY DOCUMENTS RELATED TO THE NATIONAL LABORATORY SYSTEM, INCLUDING A QUALITY ASSURANCE ACTION PLAN AND FIVE-YEAR STRATEGIC PLAN. WE ALSO STRENGTHENED REAL-TIME, COMMUNITY-BASED SURVEILLANCE FOR PRIORITY HUMAN AND ZOONOTIC DISEASES WITH EPIDEMIC POTENTIAL. AS PART OF THE DOSE PER CONTAINER PARTNERSHIP, PATH CONDUCTED FORMATIVE RESEARCH THAT CONTRIBUTED TO THE VACCINE INNOVATION PRIORITIZATION STRATEGY WORK LED BY GAVI. PATH ALSO CONDUCTED A REFRIGERATOR TEMPERATURE MONITORING STUDY IN PRIVATE PHARMACIES IN TWO URBAN DISTRICTS AND ORGANIZED COLD CHAIN MANAGEMENT TRAINING WORKSHOPS FOR THE CHIEF REGIONAL SUPPLY PHARMACISTS IN ALL 14 REGIONS OF THE COUNTRY. IN 2019, PATH PROVIDED TECHNICAL ASSISTANCE TO THE GOVERNMENT OF SENEGAL TO SCALE UP SAFE OXYGEN DELIVERY. ACTIVITIES INCLUDED QUANTIFYING THE DEMAND FOR, AND THE EXISTING IN-COUNTRY SUPPLY OF, OXYGEN. IN ADDITION, WE PROVIDED TECHNICAL ASSISTANCE TO A COALITION OF PARTNERS LED BY THE MOHSA TO COLLECT DATA ON THE AVAILABILITY OF MEDICAL DEVICES, INCLUDING OXYGEN AND PULSE OXIMETERS, WITHIN ALL PUBLIC HEALTH FACILITIES. THROUGH THE BETTER HEARTS BETTER CITIES PROJECT, PATH PUT IN PLACE AN ACTION PLAN FOR THE MOHSA AND NATIONAL SUPPLY PHARMACY TO IMPROVE THE AVAILABILITY AND ACCESSIBILITY OF HYPERTENSION MEDICATIONS. WE ALSO ESTABLISHED A COALITION OF PRIVATE COMPANIES TO RAISE AWARENESS AND INCREASE HEALTH LITERACY AROUND NONCOMMUNICABLE DISEASES. THE GOAL WAS TO CHANGE THE MINDSET FROM TREATMENT TO PREVENTION, WITH A BUSINESS CASE DEVELOPED TO DEMONSTRATE THE GAIN FOR BOTH COMPANIES AND EMPLOYEES. PATH HAS BEEN A KEY PARTNER TO THE GOVERNMENT OF SENEGAL SINCE THE INCEPTION OF ITS HPV VACCINATION DEMONSTRATION PROGRAM IN 2013. PROVIDING SUPPORT EACH YEAR, ACTIVITIES IN 2019 INCLUDED MULTI-AGE COHORT VACCINATIONS OF 9- TO 14-YEAR-OLD GIRLS. PER THE GOVERNMENT'S REQUEST, PATH CONTINUED TO ASSIST WITH PROGRAM PLANNING AND PREPARATION, SOCIAL MOBILIZATION, VACCINE DELIVERY, MONITORING AND EVALUATION, AND GRANT RENEWALS. FINALLY, AS PART OF A PROJECT FUNDED BY THE CLINTON HEALTH ACCESS INITIATIVE, PATH AND THE MOHSA WORKED TOGETHER TO TRAIN 1,672 PROVIDERS (ABOUT 200 MORE THAN ANTICIPATED) ON SELF-INJECTION OF THE CONTRACEPTIVE DMPA-SC. THE PROJECT EXCEEDED TRAINING TARGETS ACROSS ALL CADRES OF HEALTH WORKERS AND SIGNIFICANTLY CONTRIBUTED TO THE MOHSA'S OBJECTIVE OF SCALING UP DMPA-SC SELF-INJECTION NATIONWIDE. PATH IN UKRAINE ENGAGES DIRECTLY WITH KEY MOH AND NATIONAL CENTER FOR PUBLIC HEALTH (NCPH) STAKEHOLDERS TO ENSURE THAT THE PROGRAMS WE IMPLEMENT ARE ADAPTED TO THE CONTEXT OF THE COUNTRY'S ONGOING HEALTH SYSTEM REFORM. WE PROVIDE TECHNICAL ASSISTANCE TO CENTRAL-, OBLAST-, AND MUNICIPAL-LEVEL INSTITUTIONS IN DEVELOPING TB AND TB/HIV PLANS, PROTOCOLS, AND OTHER GUIDING DOCUMENTS. THE AIM IS TO ENSURE RAPID AND EFFECTIVE UPTAKE OF SUSTAINABLE, COMPREHENSIVE, HIGH-QUALITY CARE FOR ALL PATIENTS. PATH ALSO MAINTAINS STRONG RELATIONSHIPS WITH UKRAINE'S NGO AND CIVIL-SOCIETY SECTOR, ESSENTIAL PARTNERS IN REACHING MARGINALIZED GROUPS. WE WORK ACROSS THE COUNTRY, BUILDING THIS SECTOR'S CAPACITY TO PROVIDE PREVENTION, SCREENING, AND TREATMENT SUPPORT SERVICES TO TB PATIENTS, PLHIV, AND OTHER KEY POPULATIONS. NGOS AND CIVIL-SOCIETY ORGANIZATIONS FILL IMPORTANT GAPS IN THE CONTINUUM OF CARE FOR A RANGE OF CONDITIONS AND ARE OFTEN MORE TRUSTED THAN FORMAL HEALTH SERVICES. UNDER THE USAID-FUNDED SERVING LIFE PROJECT, PATH COLLABORATES WITH THE MINISTRY OF JUSTICE, MOH, AND A BROAD RANGE OF HIV, TB, AND PENITENTIARY HEALTH STAKEHOLDERS TO STRENGTHEN HIV, TB, AND HEPATITIS C SCREENING, DIAGNOSIS, TREATMENT, AND LINKAGES TO CARE (POST-RELEASE), AS DESCRIBED IN THE HIV AND TUBERCULOSIS SECTION. THIS WORK BUILDS ON A PREVIOUS PROGRAM FUNDED THROUGH TB REACH THAT LED TO A TEN-FOLD INCREASE IN TB CASE DETECTION AMONG PRETRIAL DETAINEES AND PRISONERS OVER TWO YEARS. IN 2019, PATH CLOSED OUT CHALLENGE TB (CTB) AND BEGAN A NEW PROJECT: SUPPORT TB CONTROL EFFORTS IN UKRAINE (STBCEU). CTB'S ACTIVITIES IMPROVED CASE DETECTION AND ADHERENCE TO TREATMENT AND CONTRIBUTED TOWARD NATIONWIDE CONTROL OF THE DRUG-RESISTANT TB EPIDEMIC. AMONG OTHER ACHIEVEMENTS, CTB HELPED UKRAINE INTRODUCE NEW DRUG REGIMENS THAT DRAMATICALLY IMPROVED CARE AND OUTCOMES FOR THESE PATIENTS. STBCEU PICKED UP WHERE CTB LEFT OFF AND WILL CONTINUE TO IMPROVE SERVICES AND INTRODUCE INNOVATIONS FOR TB CONTROL. THE UNITAID-FUNDED ADHERENCE SUPPORT COALITION TO END TB (ASCENT) PROJECT, FOR WHICH PATH IS A LEAD PARTNER IN UKRAINE, USES DIGITAL INNOVATIONS SUCH AS MOBILE COMMUNICATION TECHNOLOGIES TO HELP PATIENTS SUCCEED IN TREATMENT. THE ASCENT PROJECT IS GENERATING CRUCIAL EVIDENCE FOR OPTIMAL USE AND SCALE. THE LONG-TERM VISION IS A WORLD WHERE THESE DIGITAL TOOLS CAN BE AVAILABLE TO ALL TB PATIENTS, NO MATTER WHERE THEY LIVE. OVER THE LAST DECADE AND A HALF, PATH HAS ESTABLISHED ITSELF IN ZAMBIA AS A KEY AND ALL-WEATHER PARTNER FOR THE MOH. THROUGH MACEPA AND PAMO (SEE THE MALARIA AND NEGLECTED TROPICAL DISEASES SECTION), PATH SUPPORTS THE EXPANSION OF MALARIA SURVEILLANCE AND TREATMENT SERVICES. AMONG OTHER ACTIVITIES, THESE PROGRAMS STRENGTHEN IN-COUNTRY CAPACITY FOR EFFECTIVE ANALYSIS AND USE OF DATA FOR EVIDENCE-BASED DECISION-MAKING. PATH'S MALARIA WORK IN ZAMBIA SPANS SIX PROVINCES; IN 2019, EASTERN PROVINCE REACHED A NEW THRESHOLD OF LOW MALARIA PREVALENCE. IN RESPONSE, PATH, WITH ADDITIONAL FUNDING, TRAINED 1,401 COMMUNITY HEALTH WORKERS AND SET UP INTENSIFIED SURVEILLANCE SYSTEMS IN AN EFFORT TO REDUCE MALARIA INCIDENCE TO ITS LOWEST POSSIBLE LEVEL AND ACHIEVE PRE-ELIMINATION STATUS. MACEPA ALSO INTRODUCED THE CONCEPT OF COMMUNITY-BASED REACTIVE INDOOR RESIDUAL SPRAYING TO EXTEND VECTOR CONTROL COVERAGE THROUGHOUT THE YEAR IN PERENNIAL MALARIA TRANSMISSION AREAS OF SOUTHERN PROVINCE. VECTOR CONTROL IS A PROVEN AND PRIORITY INTERVENTION OF THE GOVERNMENT OF ZAMBIA TO REDUCE MALARIA. TO THIS END, PAMO SUPPORTED DEVELOPMENT OF GUIDELINES FOR EFFECTIVE AND CONTINUOUS DISTRIBUTION OF LONG-LASTING INSECTICIDE-TREATED NETS. IN 2019, PAMO DISTRIBUTED 115,416 OF THESE NETS ACROSS THE COUNTRY; 63% THROUGH A "MOP-UP" CAMPAIGN AND 37% THROUGH SCHOOLS. PATH'S EFFORTS TO ELIMINATE MALARIA EXPANDED IN 2019 TO INCLUDE RESEARCH ON A NOVEL TOOL: ATTRACTIVE TARGETED SUGAR BAITS, WHICH ARE DEPLOYED OUTSIDE OF HOMES TO ATTRACT MOSQUITOES AND PROVIDE THEM WITH A LETHAL DOSE OF INSECTICIDE. ACHIEVEMENTS IN ZAMBIA INCLUDED PRODUCT TESTING AND OPTIMIZATION BOTH IN THE LAB AND IN SEMI-FIELD SETTINGS. PATH ALSO SUPPORTED THE INTRODUCTION, TESTING, AND DOCUMENTATION OF DIGITAL TOOLS TO IMPROVE OPERATIONAL PERFORMANCE OF MASS DRUG ADMINISTRATION AND INDOOR RESIDUAL SPRAYING CAMPAIGNS IN SOUTHERN AND WESTERN PROVINCES. TB IS ANOTHER MAJOR CHALLENGE IN ZAMBIA. FOR THE PAST THREE YEARS, PATH HAS BEEN IMPLEMENTING USAID'S FLAGSHIP TB PROJECT, ERADICATE TB. OVER THE LIFE OF THE PROJECT, THE TB CURE RATE IN ZAMBIA HAS IMPROVED FROM 65% TO 70%, AND THE PROPORTION OF TB/HIV PATIENTS ON ANTIRETROVIRAL TREATMENT HAS INCREASED FROM 84% TO 93%. ALSO IN ZAMBIA, PATH CONTINUED TO ADVANCE THE AVAILABILITY OF DMPA-SC, AN INJECTABLE CONTRACEPTIVE. (SEE THE SEXUAL AND REPRODUCTIVE HEALTH SECTION.) IN 2019, PATH ROLLED OUT TRAININGS ON SELF-INJECTION TO SEVEN OUT OF TEN PROVINCES. THE TRAININGS REACHED 1,790 HEALTH CARE PROVIDERS FROM 625 HEALTH FACILITIES IN 62 DISTRICTS WHO ARE NOW ABLE TO OFFER SELF-INJECTION AS PART OF THE FAMILY PLANNING PACKAGE. |
| FORM 990, PART III, LINE 4A, DESCRIPTION OF PROGRAM SERVICE: | PATH ALSO BUILT UPON THE BETTER IMMUNIZATION DATA PROJECT BY BRINGING TOGETHER A CONSORTIUM OF TECHNICAL EXPERTS AND PARTNERS WORKING WITH THE GOVERNMENT OF ZAMBIA TOWARD A COMMON GOAL: ACCURATE, IMPROVED, AND EQUITABLE VACCINE COVERAGE RATES. THIS WORK IS FUNDED BY GAVI. KEY ACHIEVEMENTS IN 2019 INCLUDED REFRESHER TRAININGS FOR 562 HEALTH CARE WORKERS IN 320 HEALTH FACILITIES. |
| FORM 990, PART III, LINE 4B, DESCRIPTION OF PROGRAM SERVICE: | DRUG DEVELOPMENT: THROUGH OUR WORK ON DRUG DEVELOPMENT AND INTRODUCTION, PATH HELPS ENSURE THAT PEOPLE AROUND THE WORLD, ESPECIALLY CHILDREN IN LOW-RESOURCE SETTINGS, HAVE RELIABLE ACCESS TO LIFESAVING MEDICINES. OVER THE YEARS, OUR WORK HAS ADVANCED SOLUTIONS FOR A RANGE OF URGENT GLOBAL HEALTH CHALLENGES, INCLUDING ENTERIC AND DIARRHEAL DISEASES, NEGLECTED TROPICAL DISEASES, HIV/AIDS, AND MALARIA. DRAWING ON AN ENDURING COMMITMENT TO HEALTH EQUITY AND A UNIQUE PARTNERSHIP APPROACH THAT SPANS THE ACADEMIC, PRIVATE, NONPROFIT, AND GOVERNMENT SECTORS, OUR WORK OVERTURNS BARRIERS TO HEALTH AT EVERY STAGE OF DRUG DEVELOPMENT AND USE-FROM EARLY RESEARCH TO POLICY INTRODUCTION. IN 2019, THE DIARRHEA INNOVATIONS GROUP, AN INTERNATIONAL NETWORK OF CHILD HEALTH STAKEHOLDERS HOUSED WITHIN AND CO-CHAIRED BY PATH, MOVED FORWARD A CRITICAL GUIDANCE FOR DIARRHEA MANAGEMENT AMONG CHILDREN: THE ADDITION OF CO-PACKAGED ORS AND ZINC TO THE WHO ESSENTIAL MEDICINES LISTS. CO-PACKAGED ADMINISTRATION, NOW RECOGNIZED AS ESSENTIAL, COULD INCREASE ACCESS TO THIS LIFESAVING TREATMENT AND ACCELERATE PROGRESS TOWARD CHILD HEALTH GOALS. ALSO IN 2019, WE CONTINUED OUR WORK ON DEVELOPING NEW THERAPEUTICS FOR CRYPTOSPORIDIUM, A DEADLY DIARRHEA-CAUSING PARASITE FOR WHICH NO HIGHLY EFFECTIVE TREATMENT IS AVAILABLE. ADDITIONALLY, WE BEGAN ENROLLMENT IN A PHASE 2 PROOF-OF-CONCEPT CLINICAL TRIAL OF IOWH032, A NOVEL ANTISECRETORY DRUG FOR THE TREATMENT OF CHOLERA. WE ALSO CONTINUED TO ADVANCE OUR WORK ON A NEW ASSESSMENT TOOL FOR ENVIRONMENTAL ENTERIC DYSFUNCTION (EED)-AN INTESTINAL DISORDER RESPONSIBLE FOR A SIGNIFICANT PORTION OF THE GROWTH STUNTING OF APPROXIMATELY 140 MILLION CHILDREN WORLDWIDE. KNOWN AS THE "MICRONUTRIENT AND ENVIRONMENTAL ENTERIC DYSFUNCTION ASSESSMENT TOOL" (MEEDAT), THE TOOL IS DESIGNED TO MEASURE MULTIPLE BIOMARKERS, INCLUDING THOSE OF EED, SYSTEMIC INFLAMMATION, GROWTH HORMONE RESISTANCE, AND MICRONUTRIENTS. |
| FORM 990, PART III, LINE 4C, DESCRIPTION OF PROGRAM SERVICE: | MARKET DYNAMICS: PATH'S MARKET DYNAMICS PROGRAM ENCOMPASSES EFFORTS TO EVALUATE MARKETS, ASSESS SHORTCOMINGS, AND DESIGN MARKET-BASED INTERVENTIONS TO IMPROVE HEALTH OUTCOMES. THIS WORK COMPLEMENTS PATH'S OTHER EFFORTS, SUCH AS PRODUCT DEVELOPMENT AND INTRODUCTION. IT BUILDS UPON OUR EXISTING STRENGTH IN COMMERCIALIZATION, ALIGNS EXPERTISE ACROSS TEAMS, AND EXPANDS OUR CAPACITY TO ADDRESS MARKET-BASED ISSUES. IN 2019, OUR WORK FOCUSED ON ASSESSING MARKETS AND IMPROVING MARKET FUNCTIONING FOR MALARIA DRUGS AND DRUG INTERMEDIATES, MALARIA DIAGNOSTICS, AND OXYGEN THERAPY DEVICES. CENTER OF DIGITAL AND DATA EXCELLENCE: PATH USES DIGITAL TECHNOLOGIES AND DATA-LED ACTION TO IMPROVE HEALTH AND SAVE LIVES. IN 2019, THE CENTER OF DIGITAL AND DATA EXCELLENCE APPLIED ITS EXPERTISE TO SEVERAL PROJECTS. KEY ACCOMPLISHMENTS INCLUDED THE WHO-PATH STRATEGIC COLLABORATION ON INNOVATION AND GLOBAL DIGITAL HEALTH. THIS COLLABORATION BRINGS TOGETHER A CROSS-SECTOR NETWORK OF DIGITAL HEALTH EXPERTS AND INVESTORS TO SUPPORT WHO IN DEVELOPING A GLOBAL DIGITAL HEALTH DEPARTMENT AND PORTFOLIO. WORK CONTINUED UNDER DIGITAL SQUARE, A PATH-LED INITIATIVE. THIS INITIATIVE BRINGS DONORS AND PARTNERS TOGETHER TO IMPROVE HOW THE GLOBAL COMMUNITY DESIGNS, USES, AND PAYS FOR DIGITAL HEALTH TOOLS AND APPROACHES. PATH ALSO CONTINUED IMPLEMENTATION OF THE TANZANIA DATA USE PARTNERSHIP, WHICH SUPPORTS THE GOVERNMENT OF TANZANIA TO IMPROVE COUNTRYWIDE HEALTH INFORMATION SYSTEMS AND IMPLEMENT THE TANZANIA DIGITAL HEALTH INVESTMENT ROAD MAP. IN 2019, THE PARTNERSHIP SUPPORTED LAUNCH OF THE COUNTRY'S 2019-2024 NATIONAL DIGITAL HEALTH STRATEGY. THE BID INITIATIVE, A COLLABORATION BETWEEN PATH AND THE GOVERNMENTS OF TANZANIA AND ZAMBIA, HAS EMPOWERED THESE COUNTRY GOVERNMENTS TO ENHANCE IMMUNIZATION THROUGH IMPROVED DATA COLLECTION, QUALITY, AND USE. PATH CONTINUED TO SUPPORT THE SCALE-UP AND SUSTAINABILITY OF ELECTRONIC IMMUNIZATION REGISTRIES IN BOTH COUNTRIES WHILE PROVIDING MENTORSHIP AND PEER LEARNING OPPORTUNITIES TO OTHER COUNTRIES PURSUING SIMILAR DIGITAL HEALTH SOLUTIONS. IN ADDITION, PATH COLLABORATED WITH THE JOINT LEARNING NETWORK FOR UNIVERSAL HEALTH COVERAGE TO CONTINUE A PEER LEARNING MODEL THAT INCLUDES PROFESSIONALS FROM MINISTRIES OF HEALTH AND NATIONAL HEALTH INSURANCE AGENCIES IN TEN COUNTRIES. PATH ALSO INCREASED PARTICIPATION IN HIGH-LEVEL COALITIONS, INCLUDING THE DIGITAL TRANSFORMATION FOR UHC 2030 COALITION, THE LANCET/FINANCIAL TIMES JOINT COMMISSION ON GOVERNING HEALTH FUTURES 2030, AND THE DIGITAL CONNECTED CARE COALITION. |
| FORM 990, PART VI, SECTION B, LINE 11B | THE FORM 990 WAS PREPARED BY AN OUTSIDE ACCOUNTING FIRM USING INFORMATION PROVIDED BY PATH ACCOUNTING SERVICES STAFF. PATH SENIOR MANAGEMENT REVIEWED THE DRAFT FORM. A COPY OF THE DRAFT WAS SENT TO THE BOARD OF DIRECTORS FOR COMMENT. AFTER THE COMMENT PERIOD, THE CHIEF OF ACCOUNTING SIGNED THE FORM. |
| FORM 990, PART VI, SECTION B, LINE 12C | PATH HAS POLICIES AND PROCEDURES TO ADDRESS CONFLICTS OF INTEREST. PATH MANAGEMENT AND ALL STAFF AT A DESIGNATED LEVEL OR HIGHER WITHIN THE ORGANIZATION MUST COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM EACH YEAR. ALL FORMS ARE REVIEWED AND KEPT ON FILE. A CONFLICT MANAGEMENT PLAN IS DEVELOPED FOR ANY EMPLOYEE WITH A SIGNIFICANT ACTUAL OR PERCEIVED CONFLICT OF INTEREST. PATH ALSO HAS A WELL-DEFINED PROCEDURE FOR IDENTIFYING AND REPORTING ACTUAL AND POTENTIAL CONFLICTS OF INTEREST AMONG BOARD MEMBERS. NEW BOARD MEMBERS ARE ASKED TO COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM WITHIN 30 DAYS OF JOINING THE BOARD AND TO COMPLETE A NEW FORM ANNUALLY THEREAFTER. IN ADDITION, MEMBERS ARE REMINDED TO REPORT ANY NEW ISSUES THAT ARISE OUTSIDE OF THE ANNUAL DISCLOSURE PERIOD. THE DISCLOSURE FORMS ARE REVIEWED BY PATH'S GENERAL COUNSEL, AND IF ANY ACTUAL OR POTENTIAL CONFLICTS ARE IDENTIFIED, GENERAL COUNSEL MAKES A RECOMMENDATION TO THE CHAIR OF THE GOVERNANCE COMMITTEE AND THE CHAIR OF THE BOARD FOR A MANAGEMENT PLAN TO PROPERLY MANAGE ANY CONFLICTS. A FORMAL MANAGEMENT PLAN IS THEN AGREED UPON WITH THE BOARD MEMBER, AND THE ENTIRE BOARD OF DIRECTORS IS INFORMED AT THE NEXT REGULARLY SCHEDULED BOARD MEETING. |
| FORM 990, PART VI, SECTION B, LINE 15 | THE BOARD'S EXECUTIVE COMPENSATION COMMITTEE ANNUALLY REVIEWS SALARIES AND BENEFITS FOR EXECUTIVE EMPLOYEE POSITIONS AND PROVIDES GUIDANCE TO THE PRESIDENT/CHIEF EXECUTIVE OFFICER (CEO) ON COMPENSATION DECISIONS FOR EXECUTIVE POSITIONS. THE COMPENSATION AND BENEFITS FOR PATH'S PRESIDENT/CEO ARE REVIEWED AND APPROVED BY THE ENTIRE BOARD OF DIRECTORS EACH YEAR. PATH ROUTINELY USES THE SERVICES OF EXTERNAL FIRMS TO ASSESS AND BENCHMARK EXECUTIVE COMPENSATION (PRESIDENT/CEO, VICE PRESIDENTS, AND EXECUTIVE TEAM MEMBERS). THE MOST RECENT MAJOR REVIEW WAS COMPLETED BY THE BOARD COMPENSATION COMMITTEE IN 2017. AT THE REQUEST OF THE BOARD, PATH ENGAGED MERCER (A COMPENSATION, BENEFITS, AND HUMAN RESOURCES CONSULTING FIRM) TO REVIEW CURRENT AND PROPOSED BASE SALARIES OF PATH'S PRESIDENT/CEO, VICE PRESIDENTS, AND EXECUTIVE TEAM MEMBERS. MERCER USED DATA FROM MULTIPLE SOURCES TO EVALUATE CURRENT AND PROPOSED BASE SALARIES FOR THESE POSITIONS. THE BOARD'S EXECUTIVE COMPENSATION COMMITTEE REVIEWED THE MERCER REPORT AND APPROVED THE USE OF THE REPORT TO ESTABLISH A FRAMEWORK WITHIN WHICH THE PRESIDENT/CEO IS DELEGATED AUTHORITY TO ESTABLISH THE TOTAL COMPENSATION PACKAGES OF THE VICE PRESIDENTS AND EXECUTIVE TEAM MEMBERS. ADDITIONALLY, MERCER REVIEWED THE PROPOSED TOTAL COMPENSATION AND BENEFITS PACKAGE FOR THE PRESIDENT/CEO POSITION AND OBTAINED A SIGNIFICANT NUMBER OF DATA POINTS TO ASCERTAIN ITS REASONABLENESS AND APPROPRIATENESS. THE BOARD APPROVED THE COMMITTEE'S RECOMMENDATION FOR THE PRESIDENT/CEO'S TOTAL COMPENSATION PACKAGE. |
| FORM 990, PART VI, SECTION C, LINE 19 | PATH GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE TO THE PUBLIC UPON REQUEST; MOST DOCUMENTS ARE ALSO AVAILABLE ONLINE. |
Schedule R IRS990ScheduleR
Id Related Tax Exempt Org IdRelatedTaxExemptOrgGrp (4 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | EINEIN | Primary ActivitiesPrimaryActivitiesTxt | Legal Domicile StateLegalDomicileStateCd | Exempt Code SectionExemptCodeSectionTxt | Public Charity StatusPublicCharityStatusTxt | Business Name Line1DirectControllingEntityName/BusinessNameLine1Txt | Controlled OrganizationControlledOrganizationInd | Address Line1ForeignAddress/AddressLine1Txt | CityForeignAddress/CityNm | CountryForeignAddress/CountryCd | Legal Domicile Foreign CountryLegalDomicileForeignCountryCd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PATH VACCINE SOLUTIONS | ||||||||||||||
| 2201 WESTLAKE AVENUE | SEATTLE | WA | 98109 | 830431851 | ADVANCE DEVELOPMENT OF VACCINES TO IMPROVE THE HEALTH OF CHILDREN | WA | 501(C)(3) | LINE 12A, I | PATH | Yes (1) | ||||
| FOUNDATION FOR APPROPRIATE TECHNOLOGIES IN HEALTH - SWITZERLAND | ||||||||||||||
| EDUCATIONAL AND SCIENTIFIC PROMOTION OF HEALTH | 501(C)(3) | PATH | Yes (1) | 207 ROUTE DE FERNEY 1218 LE GRAND-S | GENEVA | SZ | SZ | |||||||
| PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH -KENYA | ||||||||||||||
| EDUCATIONAL AND SCIENTIFIC PROMOTION OF HEALTH | 501(C)(3) | PATH | Yes (1) | ACS PLAZA 4TH FL LENANA RD PO BOX | NAIROBI | KE | KE | |||||||
| ORGANIZATION FOR APPROPRIATE TECHNOLOGIES IN HEALTH-NIGERIA | ||||||||||||||
| EDUCATIONAL AND SCIENTIFIC PROMOTION OF HEALTH | 501(C)(3) | PATH | Yes (1) | 9TH FL ST NICHOLAS HOUSE CATHOLI | LAGOS | NI | NI | |||||||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Receipt Of Int Annts Rnts Rylts | 0 | ReceiptOfIntAnntsRntsRyltsInd |
| Gift Grnt Or Cap Contri To Oth Org | Yes (1) | GiftGrntOrCapContriToOthOrgInd |
| Gift Grnt Cap Contri From Oth Org | Yes (1) | GiftGrntCapContriFromOthOrgInd |
| Loans Or Guarantees To Other Org | 0 | LoansOrGuaranteesToOtherOrgInd |
| Loans Or Guarantees From Oth Org | 0 | LoansOrGuaranteesFromOthOrgInd |
| Div Related Organization | 0 | DivRelatedOrganizationInd |
| Asset Sale To Other Org | 0 | AssetSaleToOtherOrgInd |
| Asset Purchase From Other Org | 0 | AssetPurchaseFromOtherOrgInd |
| Asset Exchange | 0 | AssetExchangeInd |
| Rental Of Facilities To Oth Org | 0 | RentalOfFacilitiesToOthOrgInd |
| Rental Of Fclts From Oth Org | 0 | RentalOfFcltsFromOthOrgInd |
| Perform Of Services For Oth Org | 0 | PerformOfServicesForOthOrgInd |
| Perform Of Services By Other Org | 0 | PerformOfServicesByOtherOrgInd |
| Sharing Of Facilities | 0 | SharingOfFacilitiesInd |
| Paid Employees Sharing | 0 | PaidEmployeesSharingInd |
| Reimbursement Paid To Other Org | 0 | ReimbursementPaidToOtherOrgInd |
| Reimbursement Paid By Other Org | 0 | ReimbursementPaidByOtherOrgInd |
| Transfer To Other Org | 0 | TransferToOtherOrgInd |
| Transfer From Other Org | 0 | TransferFromOtherOrgInd |
Transactions Related Org TransactionsRelatedOrgGrp (3 entries)
| Transaction TypeTransactionTypeTxt | InvolvedInvolvedAmt | Method Of Amount DeterminationMethodOfAmountDeterminationTxt |
|---|---|---|
| PATH VACCINE SOLUTIONS | ||
| C | $4,265,711 | FMV |
| FOUNDATION FOR APPROPRIATE TECHNOLOGIES IN HEALTH - SWITZERLAND | ||
| B | $4,069,578 | FMV |
| PATH VACCINE SOLUTIONS | ||
| B | $92,478 | |